0001213900-25-074425.txt : 20250811 0001213900-25-074425.hdr.sgml : 20250811 20250811173123 ACCESSION NUMBER: 0001213900-25-074425 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250811 DATE AS OF CHANGE: 20250811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dominari Holdings Inc. CENTRAL INDEX KEY: 0000012239 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] ORGANIZATION NAME: 07 Trade & Services EIN: 520849320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41845 FILM NUMBER: 251203185 BUSINESS ADDRESS: STREET 1: 725 FIFTH AVENUE STREET 2: 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 393-4540 MAIL ADDRESS: STREET 1: 725 FIFTH AVENUE STREET 2: 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: AIkido Pharma Inc. DATE OF NAME CHANGE: 20210111 FORMER COMPANY: FORMER CONFORMED NAME: Aikido Pharma Inc. DATE OF NAME CHANGE: 20200317 FORMER COMPANY: FORMER CONFORMED NAME: SPHERIX INC DATE OF NAME CHANGE: 20010815 10-Q 1 ea0252311-10q_dominari.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2025

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________to ________

 

Commission File Number: 001-41845

 

DOMINARI HOLDINGS INC.
(Exact name of registrant as specified in its charter)

 

Delaware  52-0849320
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)

 

725 5th Avenue, 22nd Floor, New York, NY 10022
(Address of principal executive offices and Zip Code)

 

(212) 393-4540
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock ($0.0001 par value per share)   DOMH   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

As of August 8, 2025 there were 15,378,586 shares of the Company’s common stock issued and 15,318,438 shares outstanding.

 

 

 

 

 

 

DOMINARI HOLDINGS INC.

 

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025

 

TABLE OF CONTENTS

 

    Page
     
Part I - Financial Information  
     
Item 1. Financial Statements (Unaudited) 1
     
  Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 1
     
  Condensed Consolidated Statements of Operations for the Three and Six months ended June 30, 2025 and 2024 (Unaudited) 2
     
  Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six months ended June 30, 2025 and 2024 (Unaudited) 3
     
  Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2025 and 2024 (Unaudited) 5
     
  Notes to the Condensed Consolidated Financial Statements (Unaudited) 6
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 25
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 29
     
Item 4. Controls and Procedures 29
     
Part II - Other Information  
     
Item 1. Legal Proceedings 30
     
Item 1A. Risk Factors 30
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30
     
Item 3. Defaults Upon Senior Securities 30
     
Item 4. Mine Safety Disclosures 30
     
Item 5. Other Information 30
     
Item 6. Exhibits 31
     
Signatures 32

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Balance Sheets

($ in thousands except share and per share amounts)

 

   June 30,
2025
   December 31,
2024
 
ASSETS  (Unaudited)     
Current assets        
Cash and cash equivalents  $9,469   $4,079 
Marketable securities   18,772    5,773 
Receivable from clearing brokers   30,986    17,279 
Prepaid expenses and other assets   1,124    1,019 
Total current assets   60,351    28,150 
           
Property and equipment, net   187    239 
Notes receivable, at fair value - non-current portion   
-
    902 
Long term equity investments   43,744    12,282 
Loans to employees   1,865    2,150 
Right-of-use assets   2,733    2,944 
Security deposit   458    458 
Total assets  $109,338   $47,125 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable and accrued expenses  $2,610   $919 
Accrued commissions   13,005    2,057 
Lease liability - current   418     410 
Contract liabilities – current   436    240 
Other current liabilities   65    157 
Total current liabilities   16,534    3,783 
           
Lease liability, less current portion   2,442    2,629 
Contract liabilities, less current portion   1,762    860 
Total liabilities   20,738    7,272 
           
Stockholders’ equity          
Preferred stock, $0.0001 par value, 50,000,000 authorized   
 
    
 
 
Convertible Preferred Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding as of June 30, 2025 and December 31, 2024; liquidation value of $0.0001 per share   
-
    
-
 
Convertible Preferred Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding as of June 30, 2025 and December 31, 2024; liquidation value of $0.0001 per share   
-
    
-
 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 15,295,930 and 7,037,022 shares issued as of June 30, 2025 and December 31, 2024, respectively; 15,235,782 and 6,976,874 shares outstanding as of June 30, 2025 and December 31, 2024   
-
    
-
 
Additional paid-in capital   334,475    263,820 
Treasury stock, as of cost, 60,148 shares as of June 30, 2025 and December 31, 2024   (501)   (501)
Accumulated deficit   (246,424)   (223,466)
Non-controlling interests   1,050    
-
 
Total stockholders’ equity   88,600    39,853 
Total liabilities and stockholders’ equity  $109,338   $47,125  

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

1

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Operations

($ in thousands except share and per share amounts)

(Unaudited)

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2025   2024   2025   2024 
Revenues  $34,095   $6,174   $42,206   $7,541 
                     
Operating costs and expenses                    
General and administrative  $53,521   $8,910   $93,642   $13,082 
Total operating expenses   53,521    8,910    93,642    13,082 
Loss from operations   (19,426)   (2,736)   (51,436)   (5,541)
                     
Other income (expenses)                    
Interest income   364    285    423    449 
Gain on marketable securities, net   5,042    104    3,964    678 
Realized and unrealized gain (loss) on note receivable, net   
-
    (742)   221    (1,657)
Change in fair value of investments   31,680    (3,031)   32,000    (5,490)
Total other income (expenses)   37,086    (3,384)   36,608    (6,020)
Net income (loss)  $17,660   $(6,120)  $(14,828)  $(11,561)
                     
Less: Net profit attributable to non-controlling interests   1,050    
-
    1,050    
-
 
Net income (loss) attributable to common stockholders of Dominari Holdings Inc.  $16,610   $(6,120)  $(15,878)  $(11,561)
                     
Net income (loss) per share, basic and diluted                    
Basic and Diluted  $1.12   $(1.01)  $(1.24)  $(1.92)
                     
Weighted average number of shares outstanding, basic and diluted                    
Basic and Diluted   14,830,534    6,063,003    12,814,079    6,029,034 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

2

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

($ in thousands except share and per share amounts)

(Unaudited)

 

For the Three Months Ended June 30, 2025 and 2024

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Dominari
Holding
Stockholders’
   Non
controlling
   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
Balance at March 31, 2025   4,659   $     -    14,704,045   $-   $305,963    60,148   $(501)  $(263,034)  $42,428   $-   $42,428 
Stock-based compensation   -    -    -                26,173    -    -    -    26,173         26,173 
Issuance of common stock   -    -    591,885         2,339    -    -    -    2,339         2,339 
Shares issued under Advisory Agreements             -         -              -    -         - 
Dividends Issued                                      -    -    -      
Net income   -    -    -    -    -    -    -    16,610    16,610    1,050    17,660 
Balance at June 30, 2025   4,659   $-    15,295,930   $-   $334,475    60,148   $(501)  $(246,424)  $87,550   $1,050   $88,600 

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Dominari
Holding
Stockholders’
   Non
controlling
   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
Balance at March 31, 2024   4,659   $      -    5,995,065   $          -   $262,374    60,148   $(501)  $(214,204)  $47,669   $          -   $47,669 
Stock-based compensation   -    -    309,118    -    810    -    -    -    810    -    810 
Net loss   -    -    -    -    -    -    -    (6,120)   (6,120)   -    (6,120)
Balance at June 30, 2024   4,659   $-    6,304,183   $-   $263,184    60,148   $(501)  $(220,324)  $42,359   $-   $42,359 

  

See accompanying notes to unaudited condensed consolidated financial statements

 

3

 

 

For the Six Months Ended June 30, 2025 and 2024

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Dominari
Holding
Stockholders’
   Non
controlling
   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
Balance at December 31, 2024   4,659   $       -    7,037,022   $        -   $263,820    60,148   $(501)  $(223,466)  $39,853   $-   $39,853 
Stock-based compensation   -    
-
    1,240,969    
-
    33,855    -    
-
    
-
    33,855    
-
    33,855 
Issuance of Common Stock             3,876,054         13,517                   13,517         13,517 
Issuance of Common Stock from warrants exercised             591,885         2,339                   2,339         2,339 
Shares issued under Advisory Agreements             2,550,000         20,944                   20,944         20,944 
Dividends issued                                      (7,080)   (7,080)   
-
    (7,080)
Net (loss)/income   -    
-
    -    
-
    
-
    -    
-
    (15,878)   (15,878)   1,050    (14,828)
Balance at June 30, 2025   4,659   $-    15,295,930   $-   $334,475    60,148   $(501)  $(246,424)  $87,550   $1,050   $88,600 

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Dominari
Holding
Stockholders’
   Non
controlling
   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
Balance at December 31, 2023   4,659   $      -    5,995,065   $      -   $262,187    60,148   $(501)  $(208,763)   $52,923   $        -   $52,923 
Stock-based compensation   -    
-
    309,118    
-
    997    -    
-
    
-
    997    
-
    997 
Net loss   -    
-
    -    
-
    
-
    -    
-
    (11,561)   (11,561)   
-
    (11,561)
Balance at June 30, 2024   4,659   $-    6,304,183   $-   $263,184    60,148   $(501)  $(220,324)  $42,359   $-   $42,359 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

 

   Six Months Ended
June 30,
 
   2025   2024 
Cash flows from operating activities        
Net loss  $(14,828)  $(11,561)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Amortization of right-of-use assets   211    189 
Depreciation   52    52 
Change in carrying value of long-term investment   (32,000)   5,490 
Non-cash warrant revenue   (2,994)   
-
 
Stock-based compensation   54,799    997 
Realized loss (gain) on marketable securities   1,414    (3,330)
Unrealized (gain) loss on marketable securities   (5,185)   2,940 
Realized and unrealized (gain) loss on note receivable   (221)   1,657 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   (106)   (78)
Receivable from clearing brokers   (13,707)   (5,678)
Accounts payable and accrued expenses   1,691    (92)
Accrued salaries and benefits   
-
    65 
Accrued commissions   10,948    1,877 
Lease liabilities   (179)   (205)
Contract liabilities   1,098    
-
 
Other current liabilities   (92)   434 
Notes receivable, at fair value - net interest accrued   (20)   58 
Net cash provided by (used in) operating activities   882    (7,185)
           
Cash flows from investing activities          
Purchase of marketable securities   (13,086)   (3,963)
Sale of marketable securities   6,852    11,580 
Collection of principal on note receivable   1,143    500 
Sale of long-term equity investments   538    3,500 
Loans to employees   
-
    (1,340)
Purchase of short-term and long-term investments   
-
    (125)
Collection of loans to employees   285    2 
Net cash (used in) provided by investing activities   (4,268)   10,154 
           
Cash flows from financing activities          
Cash paid for dividends   (7,080)   
-
 
Cash received from issuance of common  stock   13,517    
 
 
Cash received from issuance of common  stock for warrants exercised   2,339    
-
 
Net cash provided by financing activities   8,776    
-
 
           
Net increase in cash and cash equivalents and restricted cash   5,390    2,969 
Cash and cash equivalents, beginning of period   4,079    2,833 
           
Cash and cash equivalents, end of period  $9,469   $5,802 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

5

 

 

DOMINARI HOLDINGS INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Dominari Labs, LLC (formerly Aikido Labs, LLC). In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker- dealer, a member of the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities is also licensed to provide investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer, a member of FINRA and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). The registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financial’s acquisition of FPS’ Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

 

On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment Manager”) which are both wholly owned subsidiaries and whose operations are included within the consolidated financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

On May 21, 2024, Dominari Financial and Heritage Strategies LLC (“HS”) entered into a Limited Liability Company Operating Agreement (the “JV Agreement”) of Dominari Financial Heritage Strategies LLC (“DFHS”). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the “Co-Managing Members”), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement.

 

6

 

 

On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”). The Company holds a ninety percent (90%) Membership Interest in each, and their operations are included within the consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding cash flows from operating and investing activities. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

As of June 30, 2025, the Company has approximately $9.5 million of cash and cash equivalents and $18.8 million of marketable securities. Additionally, the Company had approximately $31.0 million in receivable from clearing brokers. All of such funds are available to fund the Company’s operations. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations to fund its operations for at least the next twelve months from the date of the issuance of these consolidated financial statements.

 

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2024 Annual Report.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of June 30, 2025, condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024, condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2024 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2024.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

 

7

 

 

Joint Ventures

 

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of June 30, 2025, there has been no material activity in DFHS.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Receivable from Clearing Brokers

 

Receivable from Dominari Securities’ clearing brokers consisted of approximately $0.5 million in good faith deposits maintained by the Company with its clearing brokers as of June 30, 2025. The Company also has amounts with the clearing brokers held in cash in the amount of $19.1 million which consisted of $15.5 million of liquid insured deposits and $3.6 million of commissions receivable and $10.5 million of carried interest fees receivable as of June 30, 2025. The carried interest receivable was received during Q3 2025. Receivable from Dominari Securities’ clearing brokers consisted of approximately $14.4 million of liquid insured deposits, $1.3 million of commissions receivable and $0.6 million of good faith deposits maintained by the Company with its clearing brokers as of December 31, 2024. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of June 30, 2025 and December 31, 2024 an allowance for credit losses was not deemed necessary.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).

 

8

 

 

Revenue

 

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

 

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.

 

Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized.

 

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying consolidated balance sheet.

 

Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:

 

oThe Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. In determining the transaction price, an entity may include variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration is resolved. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.

 

oManagement fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.

 

9

 

 

  o Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management services. As of December 31, 2024, the Company recognized $1.1 million of contract liabilities of which $0.2 million was expected to be recognized within a year. As of June 30, 2025, the Company recognized $2.2 million of contract liabilities of which $0.4 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2030. During the six months ended June 30, 2025, the Company recognized revenue of $0.2 million that was included in contract liabilities as of June 30, 2025. During the three months ended June 30, 2025, the Company recognized revenue of $0.1 million that was included in contract liabilities as of June 30, 2025. There was no revenue associated with contract liabilities for the period ended June 30, 2024.

 

oCarried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Incentive Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to clawback or reversal. During the six months ended June 30, 2025 the Company recognized carried interest of $10.5 million which had not been received as of June 30, 2025.Such amount is included in receivable from broker on the accompanying consolidated balance sheet.

 

Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b- 1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.

 

Long-term equity investments

 

The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

 

Recently adopted accounting standards

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The standard requires all entities subject to income taxes to disclose disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirement is effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on the consolidated financial statements.

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity disclose more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its consolidated financial statements

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

 

10

 

 

Note 4. Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2025 and 2024, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2025   2024   2025   2024 
Realized gain (loss)  $(30)  $2,360   $(1,414)  $3,330 
Unrealized gain (loss)   4,975    (2,353)   5,185    (2,940)
Dividend income   97    97    193    288 
Total  $5,042   $104   $3,964   $678 

 

Note 5. Long Term Equity Investments

 

The Company holds interests in several privately held companies as long-term investments. The following table presents the Company’s long-term investments as of June 30, 2025, and December 31, 2024 ($ in thousands):

 

   December 31, 2024   June 30, 2025 
   Cost Basis   Carrying
Value
     Cost Basis   Carrying
Value
 
Investment in Kerna Health  $2,140   $4,940   $2,140   $4,940 
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*   1,000    1,000    1,000    1,000 
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass)*   170    170    170    170 
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken)**   597    364    597    364 
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*   3,500    2,248    3,500    2,248 
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) **   1,240    1,240    1,240    1,240 
Investment in Aeon Partners Fund Series DB (Databricks, Inc.)*   716    538    
-
    
-
 
Investment in Discord Inc.   476    476    476    476 
Investment in Thrasio, Inc.   300    
-
    300    
-
 
Investment in Automation Anywhere, Inc.   476    397    476    397 
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*   100    109    100    109 
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*   25    25    25    25 
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*   25    25    25    25 
Investment in AdvEn Inc.   750    750    750    750 
Investment in American Bitcoin Corp.   
-
    
-
    
-
    32,000 
Total  $11,515   $12,282   $10,799   $43,744 

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investments made in these companies are through both an SPV and direct investments.

 

11

 

 

The Company recorded an increase in the carrying values of approximately $31.7 million and a decrease of approximately $3.0 million for the three month period ended June 30, 2025 and 2024, respectively. The Company recorded an increase in the carrying values of approximately $32.0 million and a decrease of approximately $5.5 million for the six month period ended June 30, 2025 and 2024, respectively.

 

Investment in Aeon Partners Fund Series DB (Databricks, Inc.)

 

During the first quarter of 2025, the Company redeemed its interest in Databricks, Inc. for net proceeds of approximately $0.5 million, which resulted in a gain of approximately $28,000.

 

Investment in American Bitcoin Corp.

 

On February 18, 2025, the Company announced the creation of American Data Centers Inc. (“ADC”), a strategic venture focused on acquiring, building out and transforming data center campuses across the United States to meet the accelerated demand for advanced computing. On March 31, 2025, ADC completed a series of transactions providing for the launch of American Bitcoin Corp., a strategic initiative focused on industrial- scale Bitcoin mining and strategic Bitcoin reserve development and monetization (the “Transactions”). To effectuate the Transactions, ADC, Hut 8 Corp., a Delaware corporation, and certain of its subsidiaries (“Hut 8”), and the stockholders of ADC entered into a Contribution and Stock Purchase Agreement, pursuant to which Hut 8 contributed to ADC substantially all of Hut 8’s wholly owned ASIC bitcoin miners in exchange for newly issued stock representing 80% of the issued and outstanding equity interests of ADC after giving effect to the issuance. At the closing of the Transactions, ADC changed its name to American Bitcoin Corp. (“American Bitcoin”). In connection with the Transactions, American Bitcoin and Hut 8 also entered into definitive agreements providing for Hut 8 and its personnel to provide day-to-day commercial and operational management services and ASIC colocation services to American Bitcoin, in each case on an exclusive basis for so long as such agreements remain in effect. Hut 8 and its personnel will also provide back-office support services to American Bitcoin pursuant to a shared services agreement with American Bitcoin. As a result of the Transactions, American Bitcoin became a subsidiary of Hut 8 in which the Company held a 3.17% minority interest in American Bitcoin.

 

On June 27, 2025, American Bitcoin consummated a private placement (the “Private Placement”) pursuant to which it raised gross proceeds of approximately $220 million from the sale of American Bitcoin’s Class A common stock at a per share purchase price of $20. The Company’s wholly owned subsidiary, Dominari Securities, acted as placement agent for the transaction. The Company holds 1.6 million shares of American Bitcoin Class B common stock. The Class A and Class B common stock have the same rights, powers and privileges and are identical in all respects as to all matters. As a result of the Private Placement, the Company holds an approximate 2.6% minority interest in American Bitcoin and adjusted the carrying value of its 1.6 million shares of American Bitcoin’s Class B common stock, which is exchangeable with the Class A common stock on a one for one basis, to $32 million as of June 30, 2025.

 

On May 9, Gryphon Digital Mining, Inc. (NASDAQ:GRYP), a bitcoin mining company that offers carbon-neutral bitcoin mining and digital mining operations, entered into a definitive merger agreement with American Bitcoin Corp. to form a combined company that would operate under the brand American Bitcoin and be led by the board of directors of American Bitcoin. The transaction is expected to close as early as Q3 2025, and management anticipates the combined company to trade on NASDAQ under the ticker symbol “ABTC”.

 

12

 

 

Note 6. Notes Receivable

 

The following table presents the Company’s notes receivable as of June 30, 2025 and December 31, 2024 ($ in thousands):

 

June 30, 2025

 

   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair
Value
 
Notes receivable, at fair value                   
Raefan Industries LLC  06/30/2025            8%  $
         -
   $
         -
   $
        -
 
American Innovative Robotics  04/01/2027   8%  $
-
   $
-
   $
-
 
                        
Notes receivable, at fair value - current portion                    $
-
 
                        
Notes receivable, at fair value - non-current portion                    $
-
 

 

December 31, 2024

 

   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair
Value
 
Notes receivable, at fair value                   
Convergent convertible note  12/2/2024        8%  $
-
   $
           -
   $
    -
 
Raefan Industries LLC  06/30/2025   8%  $
-
   $
-
   $
-
 
American Innovative Robotics  04/01/2027   8%  $1,106   $23   $902 
                        
Notes receivable, at fair value - current portion                    $
-
 
                        
Notes receivable, at fair value - non-current portion                    $902 

 

American Innovative Robotics, LLC

 

The Company recorded interest income of approximately $20,000, and an unrealized gain on the note of approximately $221,000 on the American Innovative Robotics Promissory Note for the six months ended June 30, 2025. The note was fully paid off as of March 24, 2025 resulting in an ending value of $0.

 

Raefan Industries LLC

 

During 2024, the Company deemed that the note for Raefan Industries LLC was uncollectible, and as a result, the Company recorded a realized loss as a result of directly writing off the note on Raefan Industries LLC, resulting in an ending value of $0 for the period ended June 30, 2025 and December 31, 2024. On June 30, 2025, the Company executed a Note Modification Agreement to extend the maturity date of the note to December 31, 2025. As of June 30, 2025, the Company maintained the note as uncollectible and fully written off.

 

13

 

 

Note 7. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2025, and December 31, 2024 ($ in thousands):

 

   Fair value measured as of June 30, 2025 
       Quoted   Significant     
   Total at
June 30,
   prices in
active
markets
   other
observable
inputs
   Significant
unobservable
inputs
 
   2025    (Level 1)    (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $18,772   $11,700   $7,072   $
     -
 
Total marketable securities  $18,772   $11,700   $
-
   $
-
 
Notes receivable at fair value, current portion  $
-
   $
-
   $
-
   $
-
 
Notes receivable at fair value, non-current portion  $
-
   $
-
   $  -   $ - 

 

   Fair value measured as of December 31, 2025 
       Quoted   Significant     
       prices in   other   Significant 
   Total at
December 31,
   active
markets
   observable
inputs
   unobservable
inputs
 
   2024   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $5,773   $4,156   $1,617   $
-
 
Total marketable securities  $5,773   $4,156   $
-
   $
-
 
Notes receivable at fair value, current portion  $
-
   $
-
   $
-
   $
-
 
Notes receivable at fair value, non-current portion  $902   $
-
   $
-
   $902 

 

14

 

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Notes receivable at fair value, non-current portion at December 31, 2024  $902 
Unrealized gain (loss) on notes receivable   221 
Change in interest receivable   20 
Collection of principal and interest outstanding   (1,143)
Notes receivable at fair value, non-current portion at June 30, 2025  $
-
 
      
Notes receivable at fair value, current portion at December 31, 2023  $3,177 
Collection of principal outstanding   (500)
Realized and unrealized gain and loss on note receivable, net   (1,657)
Change in interest receivable   (56)
Notes receivable at fair value, current portion at June 30, 2024  $964 
      
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 
Unrealized loss on notes receivable   (1)
Notes receivable at fair value, non-current portion at June 30, 2024  $1,128 

 

Notes Receivable at fair value

 

As of June 30, 2025, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors.

 

Note 8. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

 

The tables below represent the Company’s lease assets and liabilities as of June 30, 2025:

 

   June 30,
2025
 
Assets:    
Operating lease right-of-use-assets  $2,733 
Liabilities:     
Current     
Operating   418 
Long-term     
Operating   2,442 
   $2,860 

 

15

 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   June 30,
2025
 
Weighted-average remaining lease term - operating leases (in years)   5.0 
Weighted-average discount rate - operating leases   10.0%

 

During the three and six months ended June 30, 2025 and 2024, the Company recorded approximately $0.2 million and 0$.4 million, respectively, of lease expense to current period operations.

 

   Three Months   Six Months 
   Ended   Ended 
   June 30,   June 30, 
   2025   2025 
Operating leases        
Operating lease cost  $178   $357 
Short-term lease rent expense   23    45 
Net rent expense  $201   $402 

 

   Three Months   Six Months 
   Ended   Ended 
   June 30,   June 30, 
   2024   2024 
Operating leases        
Operating lease cost  $178   $356 
Short-term lease rent expense   23    45 
Net rent expense  $201   $401 

 

Supplemental cash flow information related to leases were as follows:

 

   Six Months 
   Ended 
   June 30, 
   2025 
Operating cash flows - operating leases  $324 

 

As of June 30, 2025, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining Period Ended December 31, 2025   361 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   698 
Year Ended December 31, 2028   766 
Year Ended December 31, 2029   784 
Thereafter   376 
Total   3,670 
Less present value discount   (810)
Operating lease liabilities  $2,860 

 

16

 

 

Note 9. Net Income (Loss) per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period.

 

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2025, and 2024 are as follows:

 

   As of June 30, 
   2025   2024 
Convertible preferred stock   34    34 
Warrants to purchase common stock   7,517,421    444,796 
Restricted stock awards   50,000    
-
 
Options to purchase common stock   10,346,654    31,193 
Total   17,914,109    476,023 

 

Note 10. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

As of June 30, 2025, there are 15,295,930 shares of common stock issued and 15,235,782 shares outstanding.

 

On February 10, 2025, the Company entered into securities purchase agreements with certain accredited investors for the sale by the Company of 1,439,467 registered shares of its common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants in a direct offering. In a concurrent private placement, the Company entered into securities purchase agreements with certain accredited investors for the sale of 2,436,587 unregistered shares of common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants (the “February 2025 Financings”). The Series A warrants are exercisable immediately upon issuance at an exercise price of $3.72 per share and will expire five years from the date of issuance. The Series B warrants are exercisable immediately upon issuance at an exercise price of $4.22 per share and will expire five years from the date of issuance. The net proceeds to the Company from the February 2025 Financings were approximately $13.5 million.

 

On February 10, 2025, the Company entered into advisory agreements with various individuals who were issued shares of common stock. The agreements are for a term of two years but are cancellable by either party. As part of these agreements, 2,550,000 shares of common stock were issued on February 18, 2025. An additional 850,000 shares may be issued under the terms of the agreements when certain provisions are met which as of the date of grant is probable. These shares are nonforfeitable and thus were fully expensed by the Company at the time of grant. The Company used a Monte Carlo simulation to calculate the grant date fair value of the common stock. The fair value of issued shares amounted to $20,944,000 and is presented in general and administrative expenses on the consolidated statement of operations.

 

The following were assumptions used in the Company’s fair value analysis:    
     
Risk-free interest rate   4.14%
Estimated maturity date   10 years 
Underlying stock price   6.16 
Expected volatility   112.5%

 

17

 

 

The securities in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered shares, the warrants, and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

 

Certain officers, directors, employees and members of the Company’s advisory board participated in the February 2025 Financings on the same terms as the other investors.

 

During the period April 1, 2025 to June 30, 2025 warrants were exercised by various individuals resulting in additional common stock issuance of 591,885 shares generating cash proceeds of $2.3 million which is included in additional paid-in capital on the statement of equity.

 

Series D Convertible Preferred Stock

 

In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

 

As of June 30, 2025 and December 31, 2024, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.

 

Series D-1 Convertible Preferred Stock

 

The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.

 

As of June 30, 2025 and December 31, 2024, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

 

18

 

 

Dividends

 

On February 11, 2025, the board of directors approved a special cash dividend of $0.32 per share payable on March 3, 2025, to holders of common stock and certain warrant holders as of close of business on February 24, 2025. Cash dividends paid in 2025 totaled $7 million and have been charged to accumulated deficit.

 

Treasury Stock

 

There are 60,148 shares of treasury stock as of June 30, 2025.

 

Warrants

 

A summary of warrant activity for the six months ended June 30, 2025, is presented below:

 

       Weighted       Weighted
Average
Remaining
 
       Average
Exercise
   Total Intrinsic   Contractual
Life
 
   Warrants   Price   Value   (in years) 
Outstanding as of December 31, 2024   444,796   $29.25    
   -
    1.20 
Granted   7,752,108    3.97    
 
      
Expired   (87,598)  $28.74    
-
    - 
Exercised   (591,885)   3.94    
 
      
Outstanding as of June 30, 2025   7,517,421   $5.22    
-
    4.44 

 

Restricted Stock Awards and Stock Options

 

On October 7, 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”). The 2022 Plan provided for the issuance of up to 1,100,000 shares in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2022 Plan expires on January 1, 2032, and is administered by Dominari Holdings Board of Directors.

 

On February 10, 2025, the Company issued 50,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $308,000.

 

On February 10, 2025 the Company issued 351,851 shares of the Company’s common stock to Messr. Christopher Devall under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $2.1 million.

 

On February 12, 2025 in connection with the closing of the PIPE, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant to Messr. Anthony Hayes. Pursuant to the Committee’s decision, he received 500,000 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $3.4 million.

 

On March 11, 2025, the Company executed grant agreements with each of Messrs. Anthony Hayes and Kyle Wool pursuant to their employment agreements with the Company, and in accordance with the Company’s 2022 Equity Incentive Plan. Pursuant to the grant agreements, each received 154,559 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $1.7 million. Additionally, on February 10, 2025, the Company granted an additional 5 million fully vested nonqualified stock options (each, a “Performance Award” and collectively, the “Performance Awards”) each to Anthony Hayes and Kyle Wool conditioned upon either the Company’s shareholders approving the Performance Awards or approving an increase in the share reserve of the Company’s 2022 Equity Incentive Plan (the “Plan”) such that the full number of shares underlying the Performance Awards could be delivered under the Plan. On April 1, 2025, following a special meeting of shareholders, the Company’s shareholders voted to approve an increase in the Plan’s share reserve allowing the Performance Awards to be delivered under the Plan. As of June 30, 2025, the Company recorded an expense of $26.1 million for the Performance Awards.

 

19

 

 

See Restricted Stock roll-forward below.

 

A summary of restricted stock awards activity for the six months ended June 30, 2025, is presented below:

 

       Weighted 
   Number of   Average 
   Restricted
Stock Awards
   Grant Day
Fair Value
 
Nonvested at December 31, 2024   50,000   $0.98 
Granted   1,210,969   $6.11 
Vested   (1,210,969)  $2.20 
Forfeited   
-
   $
-
 
Nonvested at June 30, 2025   50,000   $0.98 

 

Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $7,657,000 and $75,000 for the six months ended June 30, 2025, and 2024, respectively. Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $12,000 and $75,000 for the three months ended June 30, 2025, and 2024, respectively All stock compensation was recorded as a component of general and administrative expenses.

 

As of June 30, 2025, there is approximately $25,000 unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2025, is presented below:

 

               Weighted 
               Average 
       Weighted   Total   Remaining 
   Number of   Average   Intrinsic   Contractual 
   Shares   Exercise Price   Value   Life (in years) 
Outstanding as of December 31, 2024   376,654   $4.29   $
-
    8.2 
Employee options granted   10,000,000   $3.85         9.8 
Employee options expired   (103,334)  $3.21    
 
      
Employee options forfeited   (307,560)  $3.47   $47,267    - 
Outstanding as of June 30, 2025   10,346,654   $3.87   $123,633    9.7 
Options vested and exercisable   10,212,604   $3.87   $74,615    9.7 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $26,198,600 and $0.1 million for the three months ended June 30, 2025, and 2024, respectively. Stock-based compensation associated with the amortization of stock option expense was approximately $33,855,000 and $0 million for the six months ended June 30, 2025, and 2024, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $68,000.

 

Non-controlling Interest

 

As previously discussed, the Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the statement of changes in equity. After June 30, 2025 the entire amount of $1.05 million attributable to non-controlling interests was distributed.

 

20

 

 

Note 11. Revenue

 

The following table presents our total revenue disaggregated by revenue type for the three and six months ended June 30, 2025 and 2024 (in thousands):

 

    Three Months Ended     Six Months Ended 
    June 30,     June 30, 
    2025   2024   2025    2024 
Underwriting  $14,954   $4,057   $20,560   $4,723 
Commissions   8,021    1,775    10,212    2,085 
Account advisory and management fees   154    96    286    437 
Carried interest fees   10,500    
-
    10,500    
-
 
Other   

466

    246    648    296 
Total  $34,095   $6,174   $42,206   $7,541 

 

Note 12. Commitments and Contingencies

 

Legal Proceedings

 

The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be.

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

 

Note 13. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2025, Dominari Securities had net capital of approximately $16.77 million, which was approximately$15.68 million in excess of net capital requirement of $1.09 million.

 

21

 

 

Note 14. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to assist in the management and building of the Company’s investment processes. Kyle Wool, one of the Company’s board members, was previously a member of the board of directors of Revere until June 2023, and held approximately 30% of Revere’s outstanding equity until May 20, 2025. From time to time, Company participates in offerings of securities as an underwriter in transactions in which Revere is also participating as an underwriter. On such transactions, the Company earned $310,405 and $103,470 in the three months ending June 30, 2025 and 2024, respectively. On such transactions, the Company earned $318,405 and $123,470 in the six months ending June 30, 2025 and 2024, respectively. As of May 20, 2025, Kyle Wool no longer holds an equity interest in Revere.

 

The Company collected fees on behalf of Series which were intended for future expenses of each Series entity. As of June 30, 2025, such amount was approximately $53,000 and is included in other current liabilities on the accompanying consolidated balance sheet.

 

During the year ended December 31, 2024, the Company entered into employee loans with various employees totaling $2.4 million. The terms of the loan agreements range from 3 years to 7 years, with an average annual interest rate of approximately 3.2%. The total interest received for the period ended June 30, 2025 was approximately $41,000. As of June 30, 2025, the total outstanding balance of the employee loans was $1.87 million included in loans to employees on the accompanying consolidated balance sheet.

 

Certain of the Company’s investments are made through related party special purpose vehicles. These are included within Note 5 of the consolidated financial statements and include the following investments: investment in Revere Master SPV Series 1 (Qxpress Pte Ltd), investment in Revere Master SPV Series VI (TessPay, Inc.), investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI), investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.), and investment in Dominari Master SPV LLC Series XII (Groq, Inc.).

 

The Company earns revenues for managing certain pooled investment vehicles which are related parties. These include the entirety of the management fee revenues ($0.2 million) included within the advisory and management fees caption within the statement of operations. As of June 30, 2025, the total amount of contract liabilities disclosed in Note 2 represented amounts received in advance of revenue earned on managing such related party investment vehicles.

 

Note 15. Segment Reporting

 

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Dominari Labs (formerly Aikido Labs), which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

 

The CODM has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.

 

22

 

 

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.

 

   Three Months Ended June 30, 2025 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue  $34,095   $
-
   $34,095 
Operating Costs               
Compensation and benefits   30,540    19,752    50,292 
Professional and consulting fees   711    495    1,206 
Data processing   177    
-
    177 
Other (income)/expenses   (742)   2,588    1,846 
Loss from operations   3,409    (22,835)   (19,426)
                
Other (expenses) income               
Interest income   364    
-
    364 
Gain on marketable securities   4,236    806    5,042 
Change in fair value of investments   
-
    31,680    31,680 
Total other (expenses) income   4,600    32,486    37,086 
Net gain  $8,009   $9,651   $17,660 
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   6,959    9,651    16,610 
Total assets   44,976    63,312    108,288 

 

   Six Months Ended June 30, 2025 
   Dominari   Legacy
AIkido
     
   Financial   Pharma   Consolidated 
Revenue  $42,206   $
-
   $42,206 
Operating Costs               
Compensation and benefits   37,430    48,557    85,987 
Professional and consulting fees   1,358    1,269    2,627 
Data processing   359    
-
    359 
Other expenses   733    3,936    4,669 
Loss from operations   2,326    (53,762)   (51,436)
                
Other (expenses) income               
Interest income   381    42    423 
Gain on marketable securities   3,326    638    3,964 
Unrealized loss on note receivable   
-
    221    221 
Change in fair value of investments   
-
    32,000    32,000 
Total other (expenses) income   3,707    32,901    36,608 
Net loss  $6,033   $(20,861)  $(14,828)
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   4,983    (20,861)   (15,878)
Total assets   44,976    63,312    108,288 

 

23

 

 

   Three Months Ended June 30, 2024 
   Dominari Financial   Legacy AIkido Pharma   Consolidated 
Revenue  $5,503   $671   $6,174 
Operating Costs               
Compensation and benefits   4,962    1,725    6,687 
Professional and consulting fees   293    168    461 
Data processing   227    12    239 
Other expenses   847    676    1,523 
Loss from operations   (826)   (1,910)   (2,736)
                
Other (expenses) income               
Interest income   205    80    285 
Gain on marketable securities   
-
    104    104 
Unrealized loss on note receivable   
-
    (742)   (742)
Change in fair value of investments   
-
    (3,031)   (3,031)
Total other (expenses) income   205    (3,589)   (3,384)
Net loss  $(621)  $(5,499)  $(6,120)
Total assets   17,361    31,712    49,073 

 

   Six Months Ended June 30, 2024 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue  $6,870   $671   $7,541 
Operating Costs               
Compensation and benefits   6,384    2,452    8,836 
Professional and consulting fees   761    657    1,418 
Data processing   375    45    420 
Other expenses   1,370    1,038    2,408 
Loss from operations   (2,020)   (3,521)   (5,541)
                
Other (expenses) income               
Interest income   341    108    449 
Gain on marketable securities   
-
    678    678 
Unrealized loss on note receivable   
-
    (1,657)   (1,657)
Change in fair value of investments   
-
    (5,490)   (5,490)
Total other (expenses) income   341    (6,361)   (6,020)
Net loss  $(1,679)  $(9,882)  $(11,561)
Total assets   17,361    31,712    49,073 

 

Note 16. Income Taxes

 

The Company recorded no income tax expense for the six months ended June 30, 2025 and 2024 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

As of June 30, 2025, and December 31, 2024, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

 

24

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. All references to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q (“Quarterly Report”) contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for the Company’s business. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Quarterly Report, words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements.

 

Overview

 

Dominari Holdings Inc. (“Dominari”) is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. Dominari and its subsidiaries are collectively referred to herein as “Company,” “we,” “our” or “us.”

 

Dominari Financial Inc. (“Dominari Financial”), a wholly-owned subsidiary of Dominari Holdings Inc., executes the Company’s growth strategy in the financial services industry. In addition to organic growth, Dominari Financial seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the financial services industry, the acquisition of 100% of a dually-registered broker dealer and investment advisor from Fieldpoint Private Bank & Trust (“Fieldpoint”), was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser was renamed Dominari Securities LLC (“Dominari Securities”) and is a wholly-owned subsidiary of Dominari Financial.

 

On October 13, 2023, the Company entered into two separate Limited Liability Company Agreements with Dominari Manager LLC (“Manager”) and Dominari IMLLC (“Investment Manager”) which are both wholly owned subsidiaries and whose operations are included within the consolidated condensed financial statements of Dominari. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

On May 21, 2024, Dominari Financial and Heritage Strategies LLC (“HS”) entered into a Limited Liability Company Operating Agreement (the “JV Agreement”) of Dominari Financial Heritage Strategies LLC (“DFHS”). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the “Co-Managing Members”), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement.

 

25

 

 

On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”) and was assigned ninety percent (90%) Membership Interest in each, which are both ninety percent (90%) majority owned subsidiaries of the Company and whose operations are included within the consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

Critical Accounting Estimates

 

We prepare our condensed consolidated financial statements in accordance with GAAP. The preparation of these condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Our actual results could differ significantly from these estimates under different assumptions and conditions.

 

There have been no material changes to our critical accounting estimates as compared to the critical accounting estimates discussed in the Form 10- K.

 

Refer to Note 3 of the Annual Report for a discussion of our significant accounting policies.

 

Recently Issued Accounting Pronouncements

 

See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards.

 

Results of Operations

 

Three months ended June 30, 2025, compared to the three months ended June 30, 2024

 

During the three months ended June 30, 2025 and 2024, we recognized approximately $34.1 million and $6.2 million in revenue from operations, respectively, primarily driven by the commissions and underwriting revenue earned by Dominari Securities and Dominari Manager LLC (“Manager”). During the three months ended June 30, 2025 we incurred net income of approximately $16.6 million and during the three months ended June 30, 2024, we incurred a net loss of approximately $6.1 million. The change in net income from operations was primarily driven by increases in overall revenues and unrealized gain on long term investments offset by increases in general and administrative costs and expenses, specifically increases in stock based compensation expense of $26 million for stock options granted and $15 million increase in commissions expense.

 

During the three months ended June 30, 2025 and 2024, other income (expenses) was approximately $37.1 million and ($3.3) million, respectively.

 

The activity described above for the three months ended June 30, 2025 and 2024, is primarily a result of the Company’s continued increase in activities related to the financial services industry, overall volatility in investment valuations due to macroeconomic uncertainty impacting marketable securities and the change in carrying value of long-term equity investments. Specifically:

 

i.Marketable securities - We recognized an unrealized gain of approximately $5.0 million and realized gain of approximately $30,000 for the three months ended June 30, 2025. The increase of approximately $5.0 million in realized and unrealized gains over the three months ended June 30, 2024, was driven by both market volatility and a fair market value adjustment on warrants held by Dominari Securities.

 

26

 

 

ii.Long-term equity investments - changes over the three months ended June 30, 2025 and 2024 are a function of observable market transactions which resulted in a increase of approximately $31.7 million on the adjusted carrying value of the investments for the three months ended June 30, 2025, which is an increase of approximately $35.0 million from the three months ended June 30, 2024 primarily driven by a markup of the investment in American Bitcoin Corp.

 

Six months ended June 30, 2025, compared to the six months ended June 30, 2024

 

During the six months ended June 30, 2025 and 2024, we recognized approximately $42.2 million and $7.5 million in revenue from operations, respectively, primarily driven by the commissions and underwriting revenue earned by Dominari Securities and Dominari Manager LLC (“Manager”). During the six months ended June 30, 2025 and 2024 we incurred net losses of approximately $15.9 million and $11.6 million, respectively. The change in net losses was primarily driven by one-time stock-based compensation paid to external advisors and management of the Company offset by overall revenues and unrealized gain on long term investments.

 

During the six months ended June 30, 2025 and 2024, other income (expenses) was approximately $36.6 million and ($6.0) million, respectively.

 

The activity described above for the six months ended June 30, 2025 and 2024, is primarily a result of the Company’s continued increase in activities related to the financial services industry, overall volatility in investment valuations due to macroeconomic uncertainty impacting marketable securities and the change in carrying value of long-term equity investments. Specifically:

 

i.Marketable securities - We recognized realized gains of approximately $1.4 million and unrealized loss of approximately $5.2 million and dividend income of $193,000 for the six months ended June 30, 2025. The increase of approximately $3.5 million in realized and unrealized gains over the six months ended June 30, 2024, was driven by both market volatility and a fair market value adjustment on warrants held by Dominari Securities..

 

ii.Notes receivable - we recognized $0.2 million realized and unrealized gain over the six months ended June 30, 2025, versus $1.7 million loss during the six months ended June 30, 2024 on notes receivable.

 

iii.Long-term equity investments - changes over the three months ended June 30, 2025 and 2024 are a function of observable market transactions which resulted in a increase of approximately $32.0 million on the adjusted carrying value of the investments for the six months ended June 30, 2025, which is an increase of approximately $37.8 million from the six months ended June 30, 2024.

 

Liquidity and Capital Resources

 

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

 

managing current cash and cash equivalents on hand from our past debt and equity offerings;

 

seeking additional funds raised through the sale of additional securities in the future; and

 

seeking additional liquidity through credit facilities or other debt arrangements.

 

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately $43.8 million as of June 30, 2025. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly traded company or from continuing operations.

 

27

 

 

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

 

The following table summarizes our net cash flows from operating, investing and financing activities for the periods indicated (in thousands):

 

   As of June 30, 
   2025   2024 
Cash provided by (used in)        
Operating activities   882    (7,185)
Investing activities   (4,268)   10,154 
Financing activities   8,776    - 
Net increase in cash   5,390    2,969 

 

Cash Flows from Operating Activities

 

For the six months ended June 30, 2025 we generated $882,000 in operations as compared to cash flow use of $7,185,000 for the six months ended June 30, 2024 The cash provided by operating activities for the six months ended June 30, 2025, is primarily attributable to increases in receivable from clearing brokers of $2.3 million, increase in accrued commissions of $10.9 million, increase in stock based comp of $53.8 million, changes in operating assets and liabilities of approximately $2.5 million, net realized and unrealized gain on marketable securities of approximately $4.1 million, offset by a net gain on long term investments of $32.0 million, increases in prepaid expenses and other assets of approximately $10.4 million, and net loss of approximately $15.9 million. The cash used in operating activities for the six months ended June 30, 2024, is primarily attributable to a net loss of approximately $11.6 million, approximately $2.9 million of unrealized gain on marketable securities, increase in clearing broker deposits of $5.7 million, partially offset by approximately $3.3 million of realized gain on marketable securities, the change in carrying value of long term investments of approximately $5.4 million, and changes in operating assets and liabilities of $2.1 million.

 

Cash Flows from Investing Activities

 

For the six months ended June 30, 2025 and 2024, net cash (used in) provided by investing activities was approximately ($4.3) million and $10.2 million, respectively. The cash used in investing activities for the six months ended June 30, 2025, primarily resulted from our purchases of marketable securities of approximately $13.2 million, partially offset by sale of marketable securities of $7.1 million collection of principal on notes receivable of $1.1 million, sale of long term investments $0.5 million and collection of principal from employee loans of $0.3 million. The cash provided by investing activities for the six months ended June 30, 2024, primarily resulted from our sale of marketable securities of approximately $11.6 million and collection of principal on notes receivable $0.5 million, and sale of long term investments of $3.5 million, partially offset by funds to employee loans $(1.3) million and purchases of marketable securities of approximately $4.0 million.

 

Cash Flows from Financing Activities

 

For the six months ended June 30, 2025, cash provided by financing activities was approximately $8.8 million, primarily driven by fund raising related to issuance of common stock of $13.5 million and issuance of common stock for warrants exercised of $2.3 million, partially offset by payment of dividends $(7.1) million. For the six months ended June 30, 2024, there are no cash flows from financing activities. Subsequent to the end of the reporting period, the Company distributed approximately $1 million to holders of non-controlling interests.

 

28

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not Applicable.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, as of June 30, 2025, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective due to the material weakness in our internal controls.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Material Weaknesses in Internal Controls

 

As of December 31, 2024, due to staffing and resource constraints, the Company required significant additional time to close the books and records. Management after year end, continued to perform its account reconciliations which required further adjustments to be recorded. As such, information technology, business processes and financial reporting controls were deemed to be ineffective due to (a) the lack of personnel to ensure the books and records are closed accurately and on a timely basis, (b) lack of proper review over the accounting for certain notes receivable accounted for at fair value, (c) the lack of appropriate segregation of duties, (d) certain general information technology control deficiencies regarding user access provisioning and administrative access review, and (e) insufficient documentation to support and evidence the design and implementation of controls.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls

 

Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

29

 

 

Part II - Other Information

 

Item 1. Legal Proceedings

 

Many aspects of the Company’s business involve substantial risks of liability. In the ordinary course of business, the Company may be named as defendant or co-defendant in various legal actions, including arbitrations, class actions and other litigation, which could create substantial exposure and periodic expenses. The Company may also be involved, from time to time, in other reviews, investigations and proceedings (both formal and informal) by governmental and self-regulatory agencies regarding the Company’s business, which may result in expenses, adverse judgments, settlements, fines, penalties, injunctions or other relief. In the past in the ordinary course of business, the Company has actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of its technology.

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

Item 1A. Risk Factors

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. Our current risk factors are set forth in our Annual Report on Form 10-K, which was filed with the SEC on April 15, 2025. Any of our previously disclosed risk factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

 

30

 

 

Item 6. Exhibits

 

31.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 
31.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  
32.2**   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*Filed herewith.

 

**Furnished herewith.

 

31

 

 

Signatures

 

Pursuant to the requirements of the Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DOMINARI HOLDINGS INC.
     
Date: August 11, 2025 By: /s/ Anthony Hayes
    Anthony Hayes
    Chief Executive Officer
    (Principal Executive Officer, Principal Financial Officer)

 

32

http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0000012239 false Q2 --12-31 0000012239 2025-01-01 2025-06-30 0000012239 2025-08-08 0000012239 2025-06-30 0000012239 2024-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2025-06-30 0000012239 us-gaap:SeriesDPreferredStockMember 2024-12-31 0000012239 domh:SeriesD1PreferredStockMember 2025-06-30 0000012239 domh:SeriesD1PreferredStockMember 2024-12-31 0000012239 2025-04-01 2025-06-30 0000012239 2024-04-01 2024-06-30 0000012239 2024-01-01 2024-06-30 0000012239 us-gaap:PreferredStockMember 2025-03-31 0000012239 us-gaap:CommonStockMember 2025-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2025-03-31 0000012239 us-gaap:RetainedEarningsMember 2025-03-31 0000012239 us-gaap:ParentMember 2025-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2025-03-31 0000012239 2025-03-31 0000012239 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000012239 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000012239 us-gaap:ParentMember 2025-04-01 2025-06-30 0000012239 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0000012239 us-gaap:PreferredStockMember 2025-06-30 0000012239 us-gaap:CommonStockMember 2025-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-06-30 0000012239 us-gaap:RetainedEarningsMember 2025-06-30 0000012239 us-gaap:ParentMember 2025-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-06-30 0000012239 us-gaap:PreferredStockMember 2024-03-31 0000012239 us-gaap:CommonStockMember 2024-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-03-31 0000012239 us-gaap:RetainedEarningsMember 2024-03-31 0000012239 us-gaap:ParentMember 2024-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2024-03-31 0000012239 2024-03-31 0000012239 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000012239 us-gaap:ParentMember 2024-04-01 2024-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0000012239 us-gaap:PreferredStockMember 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-06-30 0000012239 us-gaap:ParentMember 2024-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-06-30 0000012239 2024-06-30 0000012239 us-gaap:PreferredStockMember 2024-12-31 0000012239 us-gaap:CommonStockMember 2024-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-12-31 0000012239 us-gaap:RetainedEarningsMember 2024-12-31 0000012239 us-gaap:ParentMember 2024-12-31 0000012239 us-gaap:NoncontrollingInterestMember 2024-12-31 0000012239 us-gaap:PreferredStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-06-30 0000012239 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0000012239 us-gaap:ParentMember 2025-01-01 2025-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-06-30 0000012239 us-gaap:PreferredStockMember 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2023-12-31 0000012239 us-gaap:ParentMember 2023-12-31 0000012239 us-gaap:NoncontrollingInterestMember 2023-12-31 0000012239 2023-12-31 0000012239 us-gaap:PreferredStockMember 2024-01-01 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0000012239 us-gaap:ParentMember 2024-01-01 2024-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-06-30 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 2022-10-04 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2025-06-30 0000012239 domh:DominariFinancialHeritageStrategiesLLCMember 2024-05-21 0000012239 domh:AmericanVenturesLLCMember 2025-06-17 0000012239 2024-01-01 2024-12-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember 2025-01-01 2025-03-31 0000012239 domh:InvestmentInAmericanBitcoinCorpMember 2025-06-30 0000012239 2025-06-27 2025-06-27 0000012239 2025-06-27 0000012239 domh:AmericanBitcoinMember us-gaap:CommonClassBMember 2025-01-01 2025-06-30 0000012239 domh:InvestmentInAmericanBitcoinCorpMember us-gaap:PrivatePlacementMember 2025-06-30 0000012239 us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0000012239 us-gaap:CommonClassBMember 2025-01-01 2025-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2024-12-31 0000012239 domh:InvestmentInKernaHealthIncMember 2025-06-30 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2024-12-31 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2025-06-30 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2024-12-31 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2025-06-30 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2024-12-31 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2025-06-30 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2024-12-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2025-06-30 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2024-12-31 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2025-06-30 0000012239 domh:InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember 2024-12-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember 2025-06-30 0000012239 domh:InvestmentInDiscordIncMember 2024-12-31 0000012239 domh:InvestmentInDiscordIncMember 2025-06-30 0000012239 domh:InvestmentInThrasioIncMember 2024-12-31 0000012239 domh:InvestmentInThrasioIncMember 2025-06-30 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2024-12-31 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2025-06-30 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2024-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2025-06-30 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2024-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2025-06-30 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2024-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2025-06-30 0000012239 domh:InvestmentInAdvEnIncMember 2024-12-31 0000012239 domh:InvestmentInAdvEnIncMember 2025-06-30 0000012239 domh:InvestmentInAmericanBitcoinCorpMember 2024-12-31 0000012239 domh:InvestmentInAmericanBitcoinCorpMember 2025-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-01-01 2025-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-03-24 2025-03-24 0000012239 domh:RaefanIndustriesLLCMember 2025-01-01 2025-06-30 0000012239 domh:RaefanIndustriesLLCMember 2024-01-01 2024-12-31 0000012239 domh:RaefanIndustriesLLCMember 2025-04-01 2025-06-30 0000012239 domh:RaefanIndustriesLLCMember 2025-06-30 0000012239 domh:AmericanInnovativeRoboticsMember 2025-04-01 2025-06-30 0000012239 domh:AmericanInnovativeRoboticsMember 2025-06-30 0000012239 domh:ConvergentConvertibleNoteMember 2024-01-01 2024-12-31 0000012239 domh:ConvergentConvertibleNoteMember 2024-12-31 0000012239 domh:RaefanIndustriesLLCMember 2024-12-31 0000012239 domh:AmericanInnovativeRoboticsMember 2024-01-01 2024-12-31 0000012239 domh:AmericanInnovativeRoboticsMember 2024-12-31 0000012239 us-gaap:FairValueInputsLevel1Member 2025-06-30 0000012239 us-gaap:FairValueInputsLevel2Member 2025-06-30 0000012239 us-gaap:FairValueInputsLevel3Member 2025-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-06-30 0000012239 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-06-30 0000012239 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000012239 2022-07-11 0000012239 2023-01-11 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 us-gaap:ConvertiblePreferredStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-06-30 0000012239 us-gaap:WarrantMember 2025-01-01 2025-06-30 0000012239 us-gaap:WarrantMember 2024-01-01 2024-06-30 0000012239 us-gaap:RestrictedStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0000012239 us-gaap:EmployeeStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:EmployeeStockMember 2024-01-01 2024-06-30 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 2025-02-10 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-02-10 2025-02-10 0000012239 2025-02-10 0000012239 domh:SeriesAWarrantsMember 2025-02-10 0000012239 domh:SeriesBWarrantsMember 2025-02-10 0000012239 2025-02-10 2025-02-10 0000012239 us-gaap:CommonStockMember domh:AdvisoryAgreementsMember 2025-02-18 2025-02-18 0000012239 domh:AdvisoryAgreementsMember 2025-02-18 2025-02-18 0000012239 us-gaap:MajorityShareholderMember us-gaap:SeriesDPreferredStockMember 2025-06-30 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2025-06-30 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2024-12-31 0000012239 2025-03-03 2025-03-03 0000012239 domh:RestrictedStockAwardsMember domh:EquityIncentivePlanMember 2022-10-07 0000012239 domh:EquityIncentivePlanMember 2025-02-10 0000012239 domh:EquityIncentivePlanMember 2025-02-10 2025-02-10 0000012239 domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 0000012239 domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 2025-02-10 0000012239 domh:MessrAnthonyHayesMember 2025-02-12 2025-02-12 0000012239 domh:AnthonyHayesAndKyleWoolMember us-gaap:CommonStockMember 2025-03-11 2025-03-11 0000012239 domh:AnthonyHayesAndKyleWoolMember 2025-02-10 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000012239 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000012239 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000012239 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0000012239 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0000012239 domh:AVManagerMember 2025-06-30 0000012239 domh:AVInvestmentManagerMember 2025-06-30 0000012239 domh:NonControllingInterestMember 2025-06-30 0000012239 us-gaap:WarrantMember 2024-12-31 0000012239 us-gaap:WarrantMember 2024-12-31 2024-12-31 0000012239 us-gaap:WarrantMember 2025-01-01 2025-06-30 0000012239 us-gaap:WarrantMember 2025-06-30 0000012239 us-gaap:RestrictedStockMember 2024-12-31 0000012239 us-gaap:RestrictedStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:RestrictedStockMember 2025-06-30 0000012239 2024-12-31 2024-12-31 0000012239 domh:UnderwritingMember 2025-04-01 2025-06-30 0000012239 domh:UnderwritingMember 2024-04-01 2024-06-30 0000012239 domh:UnderwritingMember 2025-01-01 2025-06-30 0000012239 domh:UnderwritingMember 2024-01-01 2024-06-30 0000012239 domh:CommissionsMember 2025-04-01 2025-06-30 0000012239 domh:CommissionsMember 2024-04-01 2024-06-30 0000012239 domh:CommissionsMember 2025-01-01 2025-06-30 0000012239 domh:CommissionsMember 2024-01-01 2024-06-30 0000012239 domh:AdvisoryFeesMember 2025-04-01 2025-06-30 0000012239 domh:AdvisoryFeesMember 2024-04-01 2024-06-30 0000012239 domh:AdvisoryFeesMember 2025-01-01 2025-06-30 0000012239 domh:AdvisoryFeesMember 2024-01-01 2024-06-30 0000012239 domh:CarriedInterestFeesMember 2025-04-01 2025-06-30 0000012239 domh:CarriedInterestFeesMember 2024-04-01 2024-06-30 0000012239 domh:CarriedInterestFeesMember 2025-01-01 2025-06-30 0000012239 domh:CarriedInterestFeesMember 2024-01-01 2024-06-30 0000012239 domh:OtherMember 2025-04-01 2025-06-30 0000012239 domh:OtherMember 2024-04-01 2024-06-30 0000012239 domh:OtherMember 2025-01-01 2025-06-30 0000012239 domh:OtherMember 2024-01-01 2024-06-30 0000012239 domh:DominariSecuritiesMember 2025-06-30 0000012239 2023-06-30 2023-06-30 0000012239 domh:RevereSecuritiesLLCMember 2025-06-30 0000012239 srt:MinimumMember 2024-01-01 2024-12-31 0000012239 srt:MaximumMember 2024-01-01 2024-12-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-04-01 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2025-04-01 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-04-01 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-01-01 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2025-01-01 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-01-01 2025-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2024-04-01 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2024-04-01 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2024-04-01 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2024-01-01 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2024-01-01 2024-06-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2024-01-01 2024-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure domh:Segments
EX-31.1 2 ea025231101ex31-1_dominari.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
RULE 13A-14(A)/15(D)-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Anthony Hayes, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2025  
   
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)
EX-31.2 3 ea025231101ex31-2_dominari.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER PURSUANT TO
RULE 13A-14(A)/15(D)-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Anthony Hayes, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2025  
   
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Financial and Accounting Officer)
EX-32.1 4 ea025231101ex32-1_dominari.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2025, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Hayes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

Date: August 11, 2025  
   
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)

 

 

EX-32.2 5 ea025231101ex32-2_dominari.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2025, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Hayes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

Date: August 11, 2025  
   
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Financial and Accounting Officer)

 

 

EX-101.SCH 6 domh-20250630.xsd XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - Organization and Description of Business and Recent Developments link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Liquidity and Capital Resources link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Marketable Securities link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Long Term Equity Investments link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Notes Receivable link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Net Income (Loss) per Share link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Regulatory link:presentationLink link:definitionLink link:calculationLink 995319 - Disclosure - Related Party Transaction link:presentationLink link:definitionLink link:calculationLink 995320 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 995321 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Long Term Equity Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Notes Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Net Income (Loss) per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Organization and Description of Business and Recent Developments (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Liquidity and Capital Resources (Details) link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Long Term Equity Investments (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Long Term Equity Investments - Schedule of Long Term Equity Investments (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Notes Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Notes Receivable - Schedule of Notes Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Leases - Schedule of Future Minimum Payments (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Net Income (Loss) per Share - Schedule of Computation of Diluted Loss Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock - Schedule of Assumptions Used in the Company’s Fair Value Analysis (Details) link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company’s Stock Option Plan (Details) link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Regulatory (Details) link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Related Party Transaction (Details) link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Segment Reporting - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss (Details) link:presentationLink link:definitionLink link:calculationLink 996034 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 domh-20250630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 domh-20250630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 domh-20250630_lab.xml XBRL LABEL FILE EX-101.PRE 10 domh-20250630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover - shares
6 Months Ended
Jun. 30, 2025
Aug. 08, 2025
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Jun. 30, 2025  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q2  
Entity Information [Line Items]    
Entity Registrant Name DOMINARI HOLDINGS INC.  
Entity Central Index Key 0000012239  
Entity File Number 001-41845  
Entity Tax Identification Number 52-0849320  
Entity Incorporation, State or Country Code DE  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 725 5th Avenue  
Entity Address, Address Line Two 22nd Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
Entity Phone Fax Numbers [Line Items]    
City Area Code (212)  
Local Phone Number 393-4540  
Entity Listings [Line Items]    
Title of 12(b) Security Common Stock ($0.0001 par value per share)  
Trading Symbol DOMH  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   15,318,438
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets    
Cash and cash equivalents $ 9,469 $ 4,079
Marketable securities 18,772 5,773
Receivable from clearing brokers 30,986 17,279
Prepaid expenses and other assets 1,124 1,019
Total current assets 60,351 28,150
Property and equipment, net 187 239
Notes receivable, at fair value - non-current portion 902
Long term equity investments 43,744 12,282
Loans to employees 1,865 2,150
Right-of-use assets 2,733 2,944
Security deposit 458 458
Total assets 109,338 47,125
Current liabilities    
Accounts payable and accrued expenses 2,610 919
Accrued commissions 13,005 2,057
Lease liability - current 418 410
Contract liabilities – current 436 240
Other current liabilities 65 157
Total current liabilities 16,534 3,783
Lease liability, less current portion 2,442 2,629
Contract liabilities, less current portion 1,762 860
Total liabilities 20,738 7,272
Stockholders’ equity    
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 15,295,930 and 7,037,022 shares issued as of June 30, 2025 and December 31, 2024, respectively; 15,235,782 and 6,976,874 shares outstanding as of June 30, 2025 and December 31, 2024
Additional paid-in capital 334,475 263,820
Treasury stock, as of cost, 60,148 shares as of June 30, 2025 and December 31, 2024 (501) (501)
Accumulated deficit (246,424) (223,466)
Non-controlling interests 1,050
Total stockholders’ equity 88,600 39,853
Total liabilities and stockholders’ equity 109,338 47,125
Series D Convertible Preferred Stock    
Stockholders’ equity    
Preferred stock value
Series D-1 Convertible Preferred Stock    
Stockholders’ equity    
Preferred stock value
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Jun. 30, 2025
Dec. 31, 2024
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000,000 50,000,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 15,295,930 7,037,022
Common stock, shares outstanding 15,235,782 6,976,874
Treasury stock, at cost 60,148 60,148
Series D Convertible Preferred Stock    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 3,825 3,825
Preferred stock, shares outstanding 3,825 3,825
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
Series D-1 Convertible Preferred Stock    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 834 834
Preferred stock, shares outstanding 834 834
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Revenues $ 34,095 $ 6,174 $ 42,206 $ 7,541
Operating costs and expenses        
General and administrative 53,521 8,910 93,642 13,082
Total operating expenses 53,521 8,910 93,642 13,082
Loss from operations (19,426) (2,736) (51,436) (5,541)
Other income (expenses)        
Interest income 364 285 423 449
Gain on marketable securities, net 5,042 104 3,964 678
Realized and unrealized gain (loss) on note receivable, net (742) 221 (1,657)
Change in fair value of investments 31,680 (3,031) 32,000 (5,490)
Total other income (expenses) 37,086 (3,384) 36,608 (6,020)
Net income (loss) 17,660 (6,120) (14,828) (11,561)
Less: Net profit attributable to non-controlling interests 1,050 1,050
Net income (loss) attributable to common stockholders of Dominari Holdings Inc. $ 16,610 $ (6,120) $ (15,878) $ (11,561)
Net income (loss) per share, basic and diluted        
Basic (in Dollars per share) $ 1.12 $ (1.01) $ (1.24) $ (1.92)
Diluted (in Dollars per share) $ 1.12 $ (1.01) $ (1.24) $ (1.92)
Weighted average number of shares outstanding, basic and diluted        
Basic (in Shares) 14,830,534 6,063,003 12,814,079 6,029,034
Diluted (in Shares) 14,830,534 6,063,003 12,814,079 6,029,034
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Dominari Holding Stockholders’ Equity
Non controlling Interests
Total
Balance at Dec. 31, 2023 $ 262,187 $ (501) $ (208,763) $ 52,923 $ 52,923
Balance (in Shares) at Dec. 31, 2023 4,659 5,995,065            
Balance (in Shares) at Dec. 31, 2023       60,148        
Stock-based compensation 997 997 997
Stock-based compensation (in Shares)   309,118            
Net income (loss) (11,561) (11,561) (11,561)
Balance at Jun. 30, 2024 263,184 $ (501) (220,324) 42,359 42,359
Balance (in Shares) at Jun. 30, 2024 4,659 6,304,183            
Balance (in Shares) at Jun. 30, 2024       60,148        
Balance at Mar. 31, 2024 262,374 $ (501) (214,204) 47,669 47,669
Balance (in Shares) at Mar. 31, 2024 4,659 5,995,065            
Balance (in Shares) at Mar. 31, 2024       60,148        
Stock-based compensation 810 810 810
Stock-based compensation (in Shares)   309,118            
Net income (loss) (6,120) (6,120) (6,120)
Balance at Jun. 30, 2024 263,184 $ (501) (220,324) 42,359 42,359
Balance (in Shares) at Jun. 30, 2024 4,659 6,304,183            
Balance (in Shares) at Jun. 30, 2024       60,148        
Balance at Dec. 31, 2024 263,820 $ (501) (223,466) 39,853 $ 39,853
Balance (in Shares) at Dec. 31, 2024 4,659 7,037,022            
Balance (in Shares) at Dec. 31, 2024       60,148       60,148
Stock-based compensation 33,855 33,855 $ 33,855
Stock-based compensation (in Shares)   1,240,969            
Issuance of common stock     13,517     13,517   13,517
Issuance of common stock (in Shares)   3,876,054            
Issuance of Common Stock from warrants exercised     2,339     2,339   2,339
Issuance of Common Stock from warrants exercised (in Shares)   591,885            
Shares issued under Advisory Agreements     20,944     20,944   20,944
Shares issued under Advisory Agreements (in Shares)   2,550,000            
Dividends Issued         (7,080) (7,080) (7,080)
Net income (loss) (15,878) (15,878) 1,050 (14,828)
Balance at Jun. 30, 2025 334,475 $ (501) (246,424) 87,550 1,050 $ 88,600
Balance (in Shares) at Jun. 30, 2025 4,659 15,295,930            
Balance (in Shares) at Jun. 30, 2025       60,148       60,148
Balance at Mar. 31, 2025 305,963 $ (501) (263,034) 42,428 $ 42,428
Balance (in Shares) at Mar. 31, 2025 4,659 14,704,045            
Balance (in Shares) at Mar. 31, 2025       60,148        
Stock-based compensation   26,173 26,173   26,173
Issuance of common stock   2,339 2,339   $ 2,339
Issuance of common stock (in Shares)   591,885            
Issuance of Common Stock from warrants exercised (in Shares)               591,885
Shares issued under Advisory Agreements        
Dividends Issued          
Net income (loss) 16,610 16,610 1,050 17,660
Balance at Jun. 30, 2025 $ 334,475 $ (501) $ (246,424) $ 87,550 $ 1,050 $ 88,600
Balance (in Shares) at Jun. 30, 2025 4,659 15,295,930            
Balance (in Shares) at Jun. 30, 2025       60,148       60,148
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities    
Net loss $ (14,828) $ (11,561)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Amortization of right-of-use assets 211 189
Depreciation 52 52
Change in carrying value of long-term investment (32,000) 5,490
Non-cash warrant revenue (2,994)
Stock-based compensation 54,799 997
Realized loss (gain) on marketable securities 1,414 (3,330)
Unrealized (gain) loss on marketable securities (5,185) 2,940
Realized and unrealized (gain) loss on note receivable (221) 1,657
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (106) (78)
Receivable from clearing brokers (13,707) (5,678)
Accounts payable and accrued expenses 1,691 (92)
Accrued salaries and benefits 65
Accrued commissions 10,948 1,877
Lease liabilities (179) (205)
Contract liabilities 1,098
Other current liabilities (92) 434
Notes receivable, at fair value - net interest accrued (20) 58
Net cash provided by (used in) operating activities 882 (7,185)
Cash flows from investing activities    
Purchase of marketable securities (13,086) (3,963)
Sale of marketable securities 6,852 11,580
Collection of principal on note receivable 1,143 500
Sale of long-term equity investments 538 3,500
Loans to employees (1,340)
Purchase of short-term and long-term investments (125)
Collection of loans to employees 285 2
Net cash (used in) provided by investing activities (4,268) 10,154
Cash flows from financing activities    
Cash paid for dividends (7,080)
Cash received from issuance of common stock 13,517
Cash received from issuance of common stock for warrants exercised 2,339
Net cash provided by financing activities 8,776
Net increase in cash and cash equivalents and restricted cash 5,390 2,969
Cash and cash equivalents, beginning of period 4,079 2,833
Cash and cash equivalents, end of period $ 9,469 $ 5,802
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.2
Organization and Description of Business and Recent Developments
6 Months Ended
Jun. 30, 2025
Organization and Description of Business and Recent Developments [Abstract]  
Organization and Description of Business and Recent Developments

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Dominari Labs, LLC (formerly Aikido Labs, LLC). In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker- dealer, a member of the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities is also licensed to provide investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer, a member of FINRA and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). The registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financial’s acquisition of FPS’ Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

 

On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment Manager”) which are both wholly owned subsidiaries and whose operations are included within the consolidated financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

On May 21, 2024, Dominari Financial and Heritage Strategies LLC (“HS”) entered into a Limited Liability Company Operating Agreement (the “JV Agreement”) of Dominari Financial Heritage Strategies LLC (“DFHS”). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the “Co-Managing Members”), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement.

On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”). The Company holds a ninety percent (90%) Membership Interest in each, and their operations are included within the consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.25.2
Liquidity and Capital Resources
6 Months Ended
Jun. 30, 2025
Liquidity and Capital Resources [Abstract]  
Liquidity and Capital Resources

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding cash flows from operating and investing activities. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

As of June 30, 2025, the Company has approximately $9.5 million of cash and cash equivalents and $18.8 million of marketable securities. Additionally, the Company had approximately $31.0 million in receivable from clearing brokers. All of such funds are available to fund the Company’s operations. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations to fund its operations for at least the next twelve months from the date of the issuance of these consolidated financial statements.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2025
Summary of Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2024 Annual Report.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of June 30, 2025, condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024, condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2024 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2024.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Joint Ventures

 

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of June 30, 2025, there has been no material activity in DFHS.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Receivable from Clearing Brokers

 

Receivable from Dominari Securities’ clearing brokers consisted of approximately $0.5 million in good faith deposits maintained by the Company with its clearing brokers as of June 30, 2025. The Company also has amounts with the clearing brokers held in cash in the amount of $19.1 million which consisted of $15.5 million of liquid insured deposits and $3.6 million of commissions receivable and $10.5 million of carried interest fees receivable as of June 30, 2025. The carried interest receivable was received during Q3 2025. Receivable from Dominari Securities’ clearing brokers consisted of approximately $14.4 million of liquid insured deposits, $1.3 million of commissions receivable and $0.6 million of good faith deposits maintained by the Company with its clearing brokers as of December 31, 2024. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of June 30, 2025 and December 31, 2024 an allowance for credit losses was not deemed necessary.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).

Revenue

 

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

 

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.

 

Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized.

 

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying consolidated balance sheet.

 

Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:

 

oThe Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. In determining the transaction price, an entity may include variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration is resolved. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.

 

oManagement fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.
  o Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management services. As of December 31, 2024, the Company recognized $1.1 million of contract liabilities of which $0.2 million was expected to be recognized within a year. As of June 30, 2025, the Company recognized $2.2 million of contract liabilities of which $0.4 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2030. During the six months ended June 30, 2025, the Company recognized revenue of $0.2 million that was included in contract liabilities as of June 30, 2025. During the three months ended June 30, 2025, the Company recognized revenue of $0.1 million that was included in contract liabilities as of June 30, 2025. There was no revenue associated with contract liabilities for the period ended June 30, 2024.

 

oCarried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Incentive Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to clawback or reversal. During the six months ended June 30, 2025 the Company recognized carried interest of $10.5 million which had not been received as of June 30, 2025.Such amount is included in receivable from broker on the accompanying consolidated balance sheet.

 

Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b- 1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.

 

Long-term equity investments

 

The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

 

Recently adopted accounting standards

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The standard requires all entities subject to income taxes to disclose disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirement is effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on the consolidated financial statements.

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity disclose more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its consolidated financial statements

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.2
Marketable Securities
6 Months Ended
Jun. 30, 2025
Marketable Securities [Abstract]  
Marketable Securities

Note 4. Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2025 and 2024, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2025   2024   2025   2024 
Realized gain (loss)  $(30)  $2,360   $(1,414)  $3,330 
Unrealized gain (loss)   4,975    (2,353)   5,185    (2,940)
Dividend income   97    97    193    288 
Total  $5,042   $104   $3,964   $678 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.2
Long Term Equity Investments
6 Months Ended
Jun. 30, 2025
Long Term Equity Investments [Abstract]  
Long Term Equity Investments

Note 5. Long Term Equity Investments

 

The Company holds interests in several privately held companies as long-term investments. The following table presents the Company’s long-term investments as of June 30, 2025, and December 31, 2024 ($ in thousands):

 

   December 31, 2024   June 30, 2025 
   Cost Basis   Carrying
Value
     Cost Basis   Carrying
Value
 
Investment in Kerna Health  $2,140   $4,940   $2,140   $4,940 
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*   1,000    1,000    1,000    1,000 
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass)*   170    170    170    170 
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken)**   597    364    597    364 
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*   3,500    2,248    3,500    2,248 
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) **   1,240    1,240    1,240    1,240 
Investment in Aeon Partners Fund Series DB (Databricks, Inc.)*   716    538    
-
    
-
 
Investment in Discord Inc.   476    476    476    476 
Investment in Thrasio, Inc.   300    
-
    300    
-
 
Investment in Automation Anywhere, Inc.   476    397    476    397 
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*   100    109    100    109 
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*   25    25    25    25 
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*   25    25    25    25 
Investment in AdvEn Inc.   750    750    750    750 
Investment in American Bitcoin Corp.   
-
    
-
    
-
    32,000 
Total  $11,515   $12,282   $10,799   $43,744 

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investments made in these companies are through both an SPV and direct investments.

The Company recorded an increase in the carrying values of approximately $31.7 million and a decrease of approximately $3.0 million for the three month period ended June 30, 2025 and 2024, respectively. The Company recorded an increase in the carrying values of approximately $32.0 million and a decrease of approximately $5.5 million for the six month period ended June 30, 2025 and 2024, respectively.

 

Investment in Aeon Partners Fund Series DB (Databricks, Inc.)

 

During the first quarter of 2025, the Company redeemed its interest in Databricks, Inc. for net proceeds of approximately $0.5 million, which resulted in a gain of approximately $28,000.

 

Investment in American Bitcoin Corp.

 

On February 18, 2025, the Company announced the creation of American Data Centers Inc. (“ADC”), a strategic venture focused on acquiring, building out and transforming data center campuses across the United States to meet the accelerated demand for advanced computing. On March 31, 2025, ADC completed a series of transactions providing for the launch of American Bitcoin Corp., a strategic initiative focused on industrial- scale Bitcoin mining and strategic Bitcoin reserve development and monetization (the “Transactions”). To effectuate the Transactions, ADC, Hut 8 Corp., a Delaware corporation, and certain of its subsidiaries (“Hut 8”), and the stockholders of ADC entered into a Contribution and Stock Purchase Agreement, pursuant to which Hut 8 contributed to ADC substantially all of Hut 8’s wholly owned ASIC bitcoin miners in exchange for newly issued stock representing 80% of the issued and outstanding equity interests of ADC after giving effect to the issuance. At the closing of the Transactions, ADC changed its name to American Bitcoin Corp. (“American Bitcoin”). In connection with the Transactions, American Bitcoin and Hut 8 also entered into definitive agreements providing for Hut 8 and its personnel to provide day-to-day commercial and operational management services and ASIC colocation services to American Bitcoin, in each case on an exclusive basis for so long as such agreements remain in effect. Hut 8 and its personnel will also provide back-office support services to American Bitcoin pursuant to a shared services agreement with American Bitcoin. As a result of the Transactions, American Bitcoin became a subsidiary of Hut 8 in which the Company held a 3.17% minority interest in American Bitcoin.

 

On June 27, 2025, American Bitcoin consummated a private placement (the “Private Placement”) pursuant to which it raised gross proceeds of approximately $220 million from the sale of American Bitcoin’s Class A common stock at a per share purchase price of $20. The Company’s wholly owned subsidiary, Dominari Securities, acted as placement agent for the transaction. The Company holds 1.6 million shares of American Bitcoin Class B common stock. The Class A and Class B common stock have the same rights, powers and privileges and are identical in all respects as to all matters. As a result of the Private Placement, the Company holds an approximate 2.6% minority interest in American Bitcoin and adjusted the carrying value of its 1.6 million shares of American Bitcoin’s Class B common stock, which is exchangeable with the Class A common stock on a one for one basis, to $32 million as of June 30, 2025.

 

On May 9, Gryphon Digital Mining, Inc. (NASDAQ:GRYP), a bitcoin mining company that offers carbon-neutral bitcoin mining and digital mining operations, entered into a definitive merger agreement with American Bitcoin Corp. to form a combined company that would operate under the brand American Bitcoin and be led by the board of directors of American Bitcoin. The transaction is expected to close as early as Q3 2025, and management anticipates the combined company to trade on NASDAQ under the ticker symbol “ABTC”.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.2
Notes Receivable
6 Months Ended
Jun. 30, 2025
Notes Receivable [Abstract]  
Notes Receivable

Note 6. Notes Receivable

 

The following table presents the Company’s notes receivable as of June 30, 2025 and December 31, 2024 ($ in thousands):

 

June 30, 2025

 

   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair
Value
 
Notes receivable, at fair value                   
Raefan Industries LLC  06/30/2025            8%  $
         -
   $
         -
   $
        -
 
American Innovative Robotics  04/01/2027   8%  $
-
   $
-
   $
-
 
                        
Notes receivable, at fair value - current portion                    $
-
 
                        
Notes receivable, at fair value - non-current portion                    $
-
 

 

December 31, 2024

 

   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair
Value
 
Notes receivable, at fair value                   
Convergent convertible note  12/2/2024        8%  $
-
   $
           -
   $
    -
 
Raefan Industries LLC  06/30/2025   8%  $
-
   $
-
   $
-
 
American Innovative Robotics  04/01/2027   8%  $1,106   $23   $902 
                        
Notes receivable, at fair value - current portion                    $
-
 
                        
Notes receivable, at fair value - non-current portion                    $902 

 

American Innovative Robotics, LLC

 

The Company recorded interest income of approximately $20,000, and an unrealized gain on the note of approximately $221,000 on the American Innovative Robotics Promissory Note for the six months ended June 30, 2025. The note was fully paid off as of March 24, 2025 resulting in an ending value of $0.

 

Raefan Industries LLC

 

During 2024, the Company deemed that the note for Raefan Industries LLC was uncollectible, and as a result, the Company recorded a realized loss as a result of directly writing off the note on Raefan Industries LLC, resulting in an ending value of $0 for the period ended June 30, 2025 and December 31, 2024. On June 30, 2025, the Company executed a Note Modification Agreement to extend the maturity date of the note to December 31, 2025. As of June 30, 2025, the Company maintained the note as uncollectible and fully written off.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value of Financial Assets and Liabilities
6 Months Ended
Jun. 30, 2025
Fair Value of Financial Assets and Liabilities [Abstract]  
Fair Value of Financial Assets and Liabilities

Note 7. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2025, and December 31, 2024 ($ in thousands):

 

   Fair value measured as of June 30, 2025 
       Quoted   Significant     
   Total at
June 30,
   prices in
active
markets
   other
observable
inputs
   Significant
unobservable
inputs
 
   2025    (Level 1)    (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $18,772   $11,700   $7,072   $
     -
 
Total marketable securities  $18,772   $11,700   $
-
   $
-
 
Notes receivable at fair value, current portion  $
-
   $
-
   $
-
   $
-
 
Notes receivable at fair value, non-current portion  $
-
   $
-
   $  -   $ - 

 

   Fair value measured as of December 31, 2025 
       Quoted   Significant     
       prices in   other   Significant 
   Total at
December 31,
   active
markets
   observable
inputs
   unobservable
inputs
 
   2024   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $5,773   $4,156   $1,617   $
-
 
Total marketable securities  $5,773   $4,156   $
-
   $
-
 
Notes receivable at fair value, current portion  $
-
   $
-
   $
-
   $
-
 
Notes receivable at fair value, non-current portion  $902   $
-
   $
-
   $902 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Notes receivable at fair value, non-current portion at December 31, 2024  $902 
Unrealized gain (loss) on notes receivable   221 
Change in interest receivable   20 
Collection of principal and interest outstanding   (1,143)
Notes receivable at fair value, non-current portion at June 30, 2025  $
-
 
      
Notes receivable at fair value, current portion at December 31, 2023  $3,177 
Collection of principal outstanding   (500)
Realized and unrealized gain and loss on note receivable, net   (1,657)
Change in interest receivable   (56)
Notes receivable at fair value, current portion at June 30, 2024  $964 
      
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 
Unrealized loss on notes receivable   (1)
Notes receivable at fair value, non-current portion at June 30, 2024  $1,128 

 

Notes Receivable at fair value

 

As of June 30, 2025, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.25.2
Leases
6 Months Ended
Jun. 30, 2025
Leases [Abstract]  
Leases

Note 8. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

 

The tables below represent the Company’s lease assets and liabilities as of June 30, 2025:

 

   June 30,
2025
 
Assets:    
Operating lease right-of-use-assets  $2,733 
Liabilities:     
Current     
Operating   418 
Long-term     
Operating   2,442 
   $2,860 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   June 30,
2025
 
Weighted-average remaining lease term - operating leases (in years)   5.0 
Weighted-average discount rate - operating leases   10.0%

 

During the three and six months ended June 30, 2025 and 2024, the Company recorded approximately $0.2 million and 0$.4 million, respectively, of lease expense to current period operations.

 

   Three Months   Six Months 
   Ended   Ended 
   June 30,   June 30, 
   2025   2025 
Operating leases        
Operating lease cost  $178   $357 
Short-term lease rent expense   23    45 
Net rent expense  $201   $402 

 

   Three Months   Six Months 
   Ended   Ended 
   June 30,   June 30, 
   2024   2024 
Operating leases        
Operating lease cost  $178   $356 
Short-term lease rent expense   23    45 
Net rent expense  $201   $401 

 

Supplemental cash flow information related to leases were as follows:

 

   Six Months 
   Ended 
   June 30, 
   2025 
Operating cash flows - operating leases  $324 

 

As of June 30, 2025, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining Period Ended December 31, 2025   361 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   698 
Year Ended December 31, 2028   766 
Year Ended December 31, 2029   784 
Thereafter   376 
Total   3,670 
Less present value discount   (810)
Operating lease liabilities  $2,860 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.2
Net Income (Loss) per Share
6 Months Ended
Jun. 30, 2025
Net Income (Loss) per Share [Abstract]  
Net Income (Loss) per Share

Note 9. Net Income (Loss) per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period.

 

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2025, and 2024 are as follows:

 

   As of June 30, 
   2025   2024 
Convertible preferred stock   34    34 
Warrants to purchase common stock   7,517,421    444,796 
Restricted stock awards   50,000    
-
 
Options to purchase common stock   10,346,654    31,193 
Total   17,914,109    476,023 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders’ Equity and Convertible Preferred Stock
6 Months Ended
Jun. 30, 2025
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Stockholders’ Equity and Convertible Preferred Stock

Note 10. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

As of June 30, 2025, there are 15,295,930 shares of common stock issued and 15,235,782 shares outstanding.

 

On February 10, 2025, the Company entered into securities purchase agreements with certain accredited investors for the sale by the Company of 1,439,467 registered shares of its common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants in a direct offering. In a concurrent private placement, the Company entered into securities purchase agreements with certain accredited investors for the sale of 2,436,587 unregistered shares of common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants (the “February 2025 Financings”). The Series A warrants are exercisable immediately upon issuance at an exercise price of $3.72 per share and will expire five years from the date of issuance. The Series B warrants are exercisable immediately upon issuance at an exercise price of $4.22 per share and will expire five years from the date of issuance. The net proceeds to the Company from the February 2025 Financings were approximately $13.5 million.

 

On February 10, 2025, the Company entered into advisory agreements with various individuals who were issued shares of common stock. The agreements are for a term of two years but are cancellable by either party. As part of these agreements, 2,550,000 shares of common stock were issued on February 18, 2025. An additional 850,000 shares may be issued under the terms of the agreements when certain provisions are met which as of the date of grant is probable. These shares are nonforfeitable and thus were fully expensed by the Company at the time of grant. The Company used a Monte Carlo simulation to calculate the grant date fair value of the common stock. The fair value of issued shares amounted to $20,944,000 and is presented in general and administrative expenses on the consolidated statement of operations.

 

The following were assumptions used in the Company’s fair value analysis:    
     
Risk-free interest rate   4.14%
Estimated maturity date   10 years 
Underlying stock price   6.16 
Expected volatility   112.5%

The securities in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered shares, the warrants, and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

 

Certain officers, directors, employees and members of the Company’s advisory board participated in the February 2025 Financings on the same terms as the other investors.

 

During the period April 1, 2025 to June 30, 2025 warrants were exercised by various individuals resulting in additional common stock issuance of 591,885 shares generating cash proceeds of $2.3 million which is included in additional paid-in capital on the statement of equity.

 

Series D Convertible Preferred Stock

 

In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

 

As of June 30, 2025 and December 31, 2024, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.

 

Series D-1 Convertible Preferred Stock

 

The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.

 

As of June 30, 2025 and December 31, 2024, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

Dividends

 

On February 11, 2025, the board of directors approved a special cash dividend of $0.32 per share payable on March 3, 2025, to holders of common stock and certain warrant holders as of close of business on February 24, 2025. Cash dividends paid in 2025 totaled $7 million and have been charged to accumulated deficit.

 

Treasury Stock

 

There are 60,148 shares of treasury stock as of June 30, 2025.

 

Warrants

 

A summary of warrant activity for the six months ended June 30, 2025, is presented below:

 

       Weighted       Weighted
Average
Remaining
 
       Average
Exercise
   Total Intrinsic   Contractual
Life
 
   Warrants   Price   Value   (in years) 
Outstanding as of December 31, 2024   444,796   $29.25    
   -
    1.20 
Granted   7,752,108    3.97    
 
      
Expired   (87,598)  $28.74    
-
    - 
Exercised   (591,885)   3.94    
 
      
Outstanding as of June 30, 2025   7,517,421   $5.22    
-
    4.44 

 

Restricted Stock Awards and Stock Options

 

On October 7, 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”). The 2022 Plan provided for the issuance of up to 1,100,000 shares in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2022 Plan expires on January 1, 2032, and is administered by Dominari Holdings Board of Directors.

 

On February 10, 2025, the Company issued 50,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $308,000.

 

On February 10, 2025 the Company issued 351,851 shares of the Company’s common stock to Messr. Christopher Devall under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $2.1 million.

 

On February 12, 2025 in connection with the closing of the PIPE, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant to Messr. Anthony Hayes. Pursuant to the Committee’s decision, he received 500,000 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $3.4 million.

 

On March 11, 2025, the Company executed grant agreements with each of Messrs. Anthony Hayes and Kyle Wool pursuant to their employment agreements with the Company, and in accordance with the Company’s 2022 Equity Incentive Plan. Pursuant to the grant agreements, each received 154,559 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $1.7 million. Additionally, on February 10, 2025, the Company granted an additional 5 million fully vested nonqualified stock options (each, a “Performance Award” and collectively, the “Performance Awards”) each to Anthony Hayes and Kyle Wool conditioned upon either the Company’s shareholders approving the Performance Awards or approving an increase in the share reserve of the Company’s 2022 Equity Incentive Plan (the “Plan”) such that the full number of shares underlying the Performance Awards could be delivered under the Plan. On April 1, 2025, following a special meeting of shareholders, the Company’s shareholders voted to approve an increase in the Plan’s share reserve allowing the Performance Awards to be delivered under the Plan. As of June 30, 2025, the Company recorded an expense of $26.1 million for the Performance Awards.

See Restricted Stock roll-forward below.

 

A summary of restricted stock awards activity for the six months ended June 30, 2025, is presented below:

 

       Weighted 
   Number of   Average 
   Restricted
Stock Awards
   Grant Day
Fair Value
 
Nonvested at December 31, 2024   50,000   $0.98 
Granted   1,210,969   $6.11 
Vested   (1,210,969)  $2.20 
Forfeited   
-
   $
-
 
Nonvested at June 30, 2025   50,000   $0.98 

 

Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $7,657,000 and $75,000 for the six months ended June 30, 2025, and 2024, respectively. Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $12,000 and $75,000 for the three months ended June 30, 2025, and 2024, respectively All stock compensation was recorded as a component of general and administrative expenses.

 

As of June 30, 2025, there is approximately $25,000 unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2025, is presented below:

 

               Weighted 
               Average 
       Weighted   Total   Remaining 
   Number of   Average   Intrinsic   Contractual 
   Shares   Exercise Price   Value   Life (in years) 
Outstanding as of December 31, 2024   376,654   $4.29   $
-
    8.2 
Employee options granted   10,000,000   $3.85         9.8 
Employee options expired   (103,334)  $3.21    
 
      
Employee options forfeited   (307,560)  $3.47   $47,267    - 
Outstanding as of June 30, 2025   10,346,654   $3.87   $123,633    9.7 
Options vested and exercisable   10,212,604   $3.87   $74,615    9.7 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $26,198,600 and $0.1 million for the three months ended June 30, 2025, and 2024, respectively. Stock-based compensation associated with the amortization of stock option expense was approximately $33,855,000 and $0 million for the six months ended June 30, 2025, and 2024, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $68,000.

 

Non-controlling Interest

 

As previously discussed, the Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the statement of changes in equity. After June 30, 2025 the entire amount of $1.05 million attributable to non-controlling interests was distributed.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue
6 Months Ended
Jun. 30, 2025
Revenue [Abstract]  
Revenue

Note 11. Revenue

 

The following table presents our total revenue disaggregated by revenue type for the three and six months ended June 30, 2025 and 2024 (in thousands):

 

    Three Months Ended     Six Months Ended 
    June 30,     June 30, 
    2025   2024   2025    2024 
Underwriting  $14,954   $4,057   $20,560   $4,723 
Commissions   8,021    1,775    10,212    2,085 
Account advisory and management fees   154    96    286    437 
Carried interest fees   10,500    
-
    10,500    
-
 
Other   

466

    246    648    296 
Total  $34,095   $6,174   $42,206   $7,541 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.25.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2025
Commitments and Contingencies [Abstract]  
Commitments and Contingencies

Note 12. Commitments and Contingencies

 

Legal Proceedings

 

The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be.

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.2
Regulatory
6 Months Ended
Jun. 30, 2025
Regulatory [Abstract]  
Regulatory

Note 13. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2025, Dominari Securities had net capital of approximately $16.77 million, which was approximately$15.68 million in excess of net capital requirement of $1.09 million.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.2
Related Party Transaction
6 Months Ended
Jun. 30, 2025
Related Party Transaction [Abstract]  
Related Party Transaction

Note 14. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to assist in the management and building of the Company’s investment processes. Kyle Wool, one of the Company’s board members, was previously a member of the board of directors of Revere until June 2023, and held approximately 30% of Revere’s outstanding equity until May 20, 2025. From time to time, Company participates in offerings of securities as an underwriter in transactions in which Revere is also participating as an underwriter. On such transactions, the Company earned $310,405 and $103,470 in the three months ending June 30, 2025 and 2024, respectively. On such transactions, the Company earned $318,405 and $123,470 in the six months ending June 30, 2025 and 2024, respectively. As of May 20, 2025, Kyle Wool no longer holds an equity interest in Revere.

 

The Company collected fees on behalf of Series which were intended for future expenses of each Series entity. As of June 30, 2025, such amount was approximately $53,000 and is included in other current liabilities on the accompanying consolidated balance sheet.

 

During the year ended December 31, 2024, the Company entered into employee loans with various employees totaling $2.4 million. The terms of the loan agreements range from 3 years to 7 years, with an average annual interest rate of approximately 3.2%. The total interest received for the period ended June 30, 2025 was approximately $41,000. As of June 30, 2025, the total outstanding balance of the employee loans was $1.87 million included in loans to employees on the accompanying consolidated balance sheet.

 

Certain of the Company’s investments are made through related party special purpose vehicles. These are included within Note 5 of the consolidated financial statements and include the following investments: investment in Revere Master SPV Series 1 (Qxpress Pte Ltd), investment in Revere Master SPV Series VI (TessPay, Inc.), investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI), investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.), and investment in Dominari Master SPV LLC Series XII (Groq, Inc.).

 

The Company earns revenues for managing certain pooled investment vehicles which are related parties. These include the entirety of the management fee revenues ($0.2 million) included within the advisory and management fees caption within the statement of operations. As of June 30, 2025, the total amount of contract liabilities disclosed in Note 2 represented amounts received in advance of revenue earned on managing such related party investment vehicles.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 15. Segment Reporting

 

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Dominari Labs (formerly Aikido Labs), which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

 

The CODM has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.

 

   Three Months Ended June 30, 2025 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue  $34,095   $
-
   $34,095 
Operating Costs               
Compensation and benefits   30,540    19,752    50,292 
Professional and consulting fees   711    495    1,206 
Data processing   177    
-
    177 
Other (income)/expenses   (742)   2,588    1,846 
Loss from operations   3,409    (22,835)   (19,426)
                
Other (expenses) income               
Interest income   364    
-
    364 
Gain on marketable securities   4,236    806    5,042 
Change in fair value of investments   
-
    31,680    31,680 
Total other (expenses) income   4,600    32,486    37,086 
Net gain  $8,009   $9,651   $17,660 
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   6,959    9,651    16,610 
Total assets   44,976    63,312    108,288 

 

   Six Months Ended June 30, 2025 
   Dominari   Legacy
AIkido
     
   Financial   Pharma   Consolidated 
Revenue  $42,206   $
-
   $42,206 
Operating Costs               
Compensation and benefits   37,430    48,557    85,987 
Professional and consulting fees   1,358    1,269    2,627 
Data processing   359    
-
    359 
Other expenses   733    3,936    4,669 
Loss from operations   2,326    (53,762)   (51,436)
                
Other (expenses) income               
Interest income   381    42    423 
Gain on marketable securities   3,326    638    3,964 
Unrealized loss on note receivable   
-
    221    221 
Change in fair value of investments   
-
    32,000    32,000 
Total other (expenses) income   3,707    32,901    36,608 
Net loss  $6,033   $(20,861)  $(14,828)
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   4,983    (20,861)   (15,878)
Total assets   44,976    63,312    108,288 
   Three Months Ended June 30, 2024 
   Dominari Financial   Legacy AIkido Pharma   Consolidated 
Revenue  $5,503   $671   $6,174 
Operating Costs               
Compensation and benefits   4,962    1,725    6,687 
Professional and consulting fees   293    168    461 
Data processing   227    12    239 
Other expenses   847    676    1,523 
Loss from operations   (826)   (1,910)   (2,736)
                
Other (expenses) income               
Interest income   205    80    285 
Gain on marketable securities   
-
    104    104 
Unrealized loss on note receivable   
-
    (742)   (742)
Change in fair value of investments   
-
    (3,031)   (3,031)
Total other (expenses) income   205    (3,589)   (3,384)
Net loss  $(621)  $(5,499)  $(6,120)
Total assets   17,361    31,712    49,073 

 

   Six Months Ended June 30, 2024 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue  $6,870   $671   $7,541 
Operating Costs               
Compensation and benefits   6,384    2,452    8,836 
Professional and consulting fees   761    657    1,418 
Data processing   375    45    420 
Other expenses   1,370    1,038    2,408 
Loss from operations   (2,020)   (3,521)   (5,541)
                
Other (expenses) income               
Interest income   341    108    449 
Gain on marketable securities   
-
    678    678 
Unrealized loss on note receivable   
-
    (1,657)   (1,657)
Change in fair value of investments   
-
    (5,490)   (5,490)
Total other (expenses) income   341    (6,361)   (6,020)
Net loss  $(1,679)  $(9,882)  $(11,561)
Total assets   17,361    31,712    49,073 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.2
Income Taxes
6 Months Ended
Jun. 30, 2025
Income Taxes [Abstract]  
Income Taxes

Note 16. Income Taxes

 

The Company recorded no income tax expense for the six months ended June 30, 2025 and 2024 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

As of June 30, 2025, and December 31, 2024, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Pay vs Performance Disclosure        
Net Income (Loss) $ 16,610 $ (6,120) $ (15,878) $ (11,561)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.2
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.2
Accounting Policies, by Policy (Policies)
6 Months Ended
Jun. 30, 2025
Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of June 30, 2025, condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024, condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2024 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2024.

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Joint Ventures

Joint Ventures

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of June 30, 2025, there has been no material activity in DFHS.

Use of Estimates

Use of Estimates

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Receivable from Clearing Brokers

Receivable from Clearing Brokers

Receivable from Dominari Securities’ clearing brokers consisted of approximately $0.5 million in good faith deposits maintained by the Company with its clearing brokers as of June 30, 2025. The Company also has amounts with the clearing brokers held in cash in the amount of $19.1 million which consisted of $15.5 million of liquid insured deposits and $3.6 million of commissions receivable and $10.5 million of carried interest fees receivable as of June 30, 2025. The carried interest receivable was received during Q3 2025. Receivable from Dominari Securities’ clearing brokers consisted of approximately $14.4 million of liquid insured deposits, $1.3 million of commissions receivable and $0.6 million of good faith deposits maintained by the Company with its clearing brokers as of December 31, 2024. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of June 30, 2025 and December 31, 2024 an allowance for credit losses was not deemed necessary.

Leases

Leases

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).

Revenue

Revenue

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.

Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized.

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying consolidated balance sheet.
Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:
oThe Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. In determining the transaction price, an entity may include variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration is resolved. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.
oManagement fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.
  o Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management services. As of December 31, 2024, the Company recognized $1.1 million of contract liabilities of which $0.2 million was expected to be recognized within a year. As of June 30, 2025, the Company recognized $2.2 million of contract liabilities of which $0.4 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2030. During the six months ended June 30, 2025, the Company recognized revenue of $0.2 million that was included in contract liabilities as of June 30, 2025. During the three months ended June 30, 2025, the Company recognized revenue of $0.1 million that was included in contract liabilities as of June 30, 2025. There was no revenue associated with contract liabilities for the period ended June 30, 2024.
oCarried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Incentive Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to clawback or reversal. During the six months ended June 30, 2025 the Company recognized carried interest of $10.5 million which had not been received as of June 30, 2025.Such amount is included in receivable from broker on the accompanying consolidated balance sheet.
Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b- 1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.
Long-term equity investments

Long-term equity investments

The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

Recently adopted accounting standards

Recently adopted accounting standards

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The standard requires all entities subject to income taxes to disclose disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirement is effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on the consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity disclose more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its consolidated financial statements

Effect of new accounting pronouncements to be adopted in future periods

Effect of new accounting pronouncements to be adopted in future periods

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.2
Marketable Securities (Tables)
6 Months Ended
Jun. 30, 2025
Marketable Securities [Abstract]  
Schedule of Gains and (Losses) on Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2025 and 2024, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows
   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2025   2024   2025   2024 
Realized gain (loss)  $(30)  $2,360   $(1,414)  $3,330 
Unrealized gain (loss)   4,975    (2,353)   5,185    (2,940)
Dividend income   97    97    193    288 
Total  $5,042   $104   $3,964   $678 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.2
Long Term Equity Investments (Tables)
6 Months Ended
Jun. 30, 2025
Long-Term Equity Investments [Abstract]  
Schedule of Long Term Equity Investments The following table presents the Company’s long-term investments as of June 30, 2025, and December 31, 2024
   December 31, 2024   June 30, 2025 
   Cost Basis   Carrying
Value
     Cost Basis   Carrying
Value
 
Investment in Kerna Health  $2,140   $4,940   $2,140   $4,940 
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*   1,000    1,000    1,000    1,000 
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass)*   170    170    170    170 
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken)**   597    364    597    364 
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*   3,500    2,248    3,500    2,248 
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) **   1,240    1,240    1,240    1,240 
Investment in Aeon Partners Fund Series DB (Databricks, Inc.)*   716    538    
-
    
-
 
Investment in Discord Inc.   476    476    476    476 
Investment in Thrasio, Inc.   300    
-
    300    
-
 
Investment in Automation Anywhere, Inc.   476    397    476    397 
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*   100    109    100    109 
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*   25    25    25    25 
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*   25    25    25    25 
Investment in AdvEn Inc.   750    750    750    750 
Investment in American Bitcoin Corp.   
-
    
-
    
-
    32,000 
Total  $11,515   $12,282   $10,799   $43,744 

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investments made in these companies are through both an SPV and direct investments.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.2
Notes Receivable (Tables)
6 Months Ended
Jun. 30, 2025
Notes Receivable [Abstract]  
Schedule of Notes Receivable

The following table presents the Company’s notes receivable as of June 30, 2025 and December 31, 2024 ($ in thousands):

   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair
Value
 
Notes receivable, at fair value                   
Raefan Industries LLC  06/30/2025            8%  $
         -
   $
         -
   $
        -
 
American Innovative Robotics  04/01/2027   8%  $
-
   $
-
   $
-
 
                        
Notes receivable, at fair value - current portion                    $
-
 
                        
Notes receivable, at fair value - non-current portion                    $
-
 
   Maturity
Date
  Stated
Interest
Rate
   Principal
Amount
   Interest
Receivable
   Fair
Value
 
Notes receivable, at fair value                   
Convergent convertible note  12/2/2024        8%  $
-
   $
           -
   $
    -
 
Raefan Industries LLC  06/30/2025   8%  $
-
   $
-
   $
-
 
American Innovative Robotics  04/01/2027   8%  $1,106   $23   $902 
                        
Notes receivable, at fair value - current portion                    $
-
 
                        
Notes receivable, at fair value - non-current portion                    $902 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value of Financial Assets and Liabilities (Tables)
6 Months Ended
Jun. 30, 2025
Fair Value of Financial Assets and Liabilities [Abstract]  
Schedule of Assets and Liabilities that are Measured at Fair Value

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2025, and December 31, 2024 ($ in thousands):

 

   Fair value measured as of June 30, 2025 
       Quoted   Significant     
   Total at
June 30,
   prices in
active
markets
   other
observable
inputs
   Significant
unobservable
inputs
 
   2025    (Level 1)    (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $18,772   $11,700   $7,072   $
     -
 
Total marketable securities  $18,772   $11,700   $
-
   $
-
 
Notes receivable at fair value, current portion  $
-
   $
-
   $
-
   $
-
 
Notes receivable at fair value, non-current portion  $
-
   $
-
   $  -   $ - 

 

   Fair value measured as of December 31, 2025 
       Quoted   Significant     
       prices in   other   Significant 
   Total at
December 31,
   active
markets
   observable
inputs
   unobservable
inputs
 
   2024   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                
Equities  $5,773   $4,156   $1,617   $
-
 
Total marketable securities  $5,773   $4,156   $
-
   $
-
 
Notes receivable at fair value, current portion  $
-
   $
-
   $
-
   $
-
 
Notes receivable at fair value, non-current portion  $902   $
-
   $
-
   $902 
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Notes receivable at fair value, non-current portion at December 31, 2024  $902 
Unrealized gain (loss) on notes receivable   221 
Change in interest receivable   20 
Collection of principal and interest outstanding   (1,143)
Notes receivable at fair value, non-current portion at June 30, 2025  $
-
 
      
Notes receivable at fair value, current portion at December 31, 2023  $3,177 
Collection of principal outstanding   (500)
Realized and unrealized gain and loss on note receivable, net   (1,657)
Change in interest receivable   (56)
Notes receivable at fair value, current portion at June 30, 2024  $964 
      
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 
Unrealized loss on notes receivable   (1)
Notes receivable at fair value, non-current portion at June 30, 2024  $1,128 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.2
Leases (Tables)
6 Months Ended
Jun. 30, 2025
Leases [Abstract]  
Schedule of Lease Assets and Liabilities

The tables below represent the Company’s lease assets and liabilities as of June 30, 2025:

 

   June 30,
2025
 
Assets:    
Operating lease right-of-use-assets  $2,733 
Liabilities:     
Current     
Operating   418 
Long-term     
Operating   2,442 
   $2,860 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   June 30,
2025
 
Weighted-average remaining lease term - operating leases (in years)   5.0 
Weighted-average discount rate - operating leases   10.0%

 

During the three and six months ended June 30, 2025 and 2024, the Company recorded approximately $0.2 million and 0$.4 million, respectively, of lease expense to current period operations.

 

   Three Months   Six Months 
   Ended   Ended 
   June 30,   June 30, 
   2025   2025 
Operating leases        
Operating lease cost  $178   $357 
Short-term lease rent expense   23    45 
Net rent expense  $201   $402 

 

   Three Months   Six Months 
   Ended   Ended 
   June 30,   June 30, 
   2024   2024 
Operating leases        
Operating lease cost  $178   $356 
Short-term lease rent expense   23    45 
Net rent expense  $201   $401 

 

Supplemental cash flow information related to leases were as follows:

 

   Six Months 
   Ended 
   June 30, 
   2025 
Operating cash flows - operating leases  $324 
Schedule of Future Minimum Payments

As of June 30, 2025, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining Period Ended December 31, 2025   361 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   698 
Year Ended December 31, 2028   766 
Year Ended December 31, 2029   784 
Thereafter   376 
Total   3,670 
Less present value discount   (810)
Operating lease liabilities  $2,860 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.2
Net Income (Loss) per Share (Tables)
6 Months Ended
Jun. 30, 2025
Net Income (Loss) per Share [Abstract]  
Schedule of Computation of Diluted Loss Per Share

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2025, and 2024 are as follows:

 

   As of June 30, 
   2025   2024 
Convertible preferred stock   34    34 
Warrants to purchase common stock   7,517,421    444,796 
Restricted stock awards   50,000    
-
 
Options to purchase common stock   10,346,654    31,193 
Total   17,914,109    476,023 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders’ Equity and Convertible Preferred Stock (Tables)
6 Months Ended
Jun. 30, 2025
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Schedule of Assumptions Used in the Company’s Fair Value Analysis
The following were assumptions used in the Company’s fair value analysis:    
     
Risk-free interest rate   4.14%
Estimated maturity date   10 years 
Underlying stock price   6.16 
Expected volatility   112.5%
Schedule of Warrant Activity

A summary of warrant activity for the six months ended June 30, 2025, is presented below:

 

       Weighted       Weighted
Average
Remaining
 
       Average
Exercise
   Total Intrinsic   Contractual
Life
 
   Warrants   Price   Value   (in years) 
Outstanding as of December 31, 2024   444,796   $29.25    
   -
    1.20 
Granted   7,752,108    3.97    
 
      
Expired   (87,598)  $28.74    
-
    - 
Exercised   (591,885)   3.94    
 
      
Outstanding as of June 30, 2025   7,517,421   $5.22    
-
    4.44 
Schedule of Restricted Stock Awards Activity

A summary of restricted stock awards activity for the six months ended June 30, 2025, is presented below:

 

       Weighted 
   Number of   Average 
   Restricted
Stock Awards
   Grant Day
Fair Value
 
Nonvested at December 31, 2024   50,000   $0.98 
Granted   1,210,969   $6.11 
Vested   (1,210,969)  $2.20 
Forfeited   
-
   $
-
 
Nonvested at June 30, 2025   50,000   $0.98 
Schedule of Option Activity Under the Company’s Stock Option Plan

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2025, is presented below:

 

               Weighted 
               Average 
       Weighted   Total   Remaining 
   Number of   Average   Intrinsic   Contractual 
   Shares   Exercise Price   Value   Life (in years) 
Outstanding as of December 31, 2024   376,654   $4.29   $
-
    8.2 
Employee options granted   10,000,000   $3.85         9.8 
Employee options expired   (103,334)  $3.21    
 
      
Employee options forfeited   (307,560)  $3.47   $47,267    - 
Outstanding as of June 30, 2025   10,346,654   $3.87   $123,633    9.7 
Options vested and exercisable   10,212,604   $3.87   $74,615    9.7 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2025
Revenue [Abstract]  
Schedule of Total Revenue Disaggregated by Revenue Type

The following table presents our total revenue disaggregated by revenue type for the three and six months ended June 30, 2025 and 2024 (in thousands):

 

    Three Months Ended     Six Months Ended 
    June 30,     June 30, 
    2025   2024   2025    2024 
Underwriting  $14,954   $4,057   $20,560   $4,723 
Commissions   8,021    1,775    10,212    2,085 
Account advisory and management fees   154    96    286    437 
Carried interest fees   10,500    
-
    10,500    
-
 
Other   

466

    246    648    296 
Total  $34,095   $6,174   $42,206   $7,541 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.

 

   Three Months Ended June 30, 2025 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue  $34,095   $
-
   $34,095 
Operating Costs               
Compensation and benefits   30,540    19,752    50,292 
Professional and consulting fees   711    495    1,206 
Data processing   177    
-
    177 
Other (income)/expenses   (742)   2,588    1,846 
Loss from operations   3,409    (22,835)   (19,426)
                
Other (expenses) income               
Interest income   364    
-
    364 
Gain on marketable securities   4,236    806    5,042 
Change in fair value of investments   
-
    31,680    31,680 
Total other (expenses) income   4,600    32,486    37,086 
Net gain  $8,009   $9,651   $17,660 
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   6,959    9,651    16,610 
Total assets   44,976    63,312    108,288 

 

   Six Months Ended June 30, 2025 
   Dominari   Legacy
AIkido
     
   Financial   Pharma   Consolidated 
Revenue  $42,206   $
-
   $42,206 
Operating Costs               
Compensation and benefits   37,430    48,557    85,987 
Professional and consulting fees   1,358    1,269    2,627 
Data processing   359    
-
    359 
Other expenses   733    3,936    4,669 
Loss from operations   2,326    (53,762)   (51,436)
                
Other (expenses) income               
Interest income   381    42    423 
Gain on marketable securities   3,326    638    3,964 
Unrealized loss on note receivable   
-
    221    221 
Change in fair value of investments   
-
    32,000    32,000 
Total other (expenses) income   3,707    32,901    36,608 
Net loss  $6,033   $(20,861)  $(14,828)
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   4,983    (20,861)   (15,878)
Total assets   44,976    63,312    108,288 
   Three Months Ended June 30, 2024 
   Dominari Financial   Legacy AIkido Pharma   Consolidated 
Revenue  $5,503   $671   $6,174 
Operating Costs               
Compensation and benefits   4,962    1,725    6,687 
Professional and consulting fees   293    168    461 
Data processing   227    12    239 
Other expenses   847    676    1,523 
Loss from operations   (826)   (1,910)   (2,736)
                
Other (expenses) income               
Interest income   205    80    285 
Gain on marketable securities   
-
    104    104 
Unrealized loss on note receivable   
-
    (742)   (742)
Change in fair value of investments   
-
    (3,031)   (3,031)
Total other (expenses) income   205    (3,589)   (3,384)
Net loss  $(621)  $(5,499)  $(6,120)
Total assets   17,361    31,712    49,073 

 

   Six Months Ended June 30, 2024 
   Dominari
Financial
   Legacy
AIkido
Pharma
   Consolidated 
Revenue  $6,870   $671   $7,541 
Operating Costs               
Compensation and benefits   6,384    2,452    8,836 
Professional and consulting fees   761    657    1,418 
Data processing   375    45    420 
Other expenses   1,370    1,038    2,408 
Loss from operations   (2,020)   (3,521)   (5,541)
                
Other (expenses) income               
Interest income   341    108    449 
Gain on marketable securities   
-
    678    678 
Unrealized loss on note receivable   
-
    (1,657)   (1,657)
Change in fair value of investments   
-
    (5,490)   (5,490)
Total other (expenses) income   341    (6,361)   (6,020)
Net loss  $(1,679)  $(9,882)  $(11,561)
Total assets   17,361    31,712    49,073 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Organization and Description of Business and Recent Developments (Details) - USD ($)
$ in Millions
6 Months Ended
Oct. 04, 2022
Jun. 30, 2025
Jun. 17, 2025
May 21, 2024
Sep. 09, 2022
Organization and Description of Business and Recent Developments [Line Items]          
Additional seller paid (in Dollars) $ 2.0 $ 1.4      
Dominari Financial Heritage Strategies LLC [Member]          
Organization and Description of Business and Recent Developments [Line Items]          
Ownership interests       50.00%  
FPS Purchase Agreement [Member]          
Organization and Description of Business and Recent Developments [Line Items]          
Membership interests 20.00% 80.00%     100.00%
American Ventures LLC [Member]          
Organization and Description of Business and Recent Developments [Line Items]          
Membership interests     90.00%    
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.2
Liquidity and Capital Resources (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Liquidity and Capital Resources [Abstract]    
Cash and cash equivalents $ 9,469 $ 4,079
Marketable securities 18,772 $ 5,773
Receivable from clearing brokers $ 31,000  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2025
Dec. 31, 2024
May 21, 2024
Summary of Significant Accounting Policies [Line Items]        
Liquid insured deposits $ 0.5 $ 0.5 $ 14.4  
Cash 19.1 19.1    
Good faith deposits 15.5 15.5 0.6  
Commissions receivable 3.6 3.6 1.3  
Commissions receivable   10.5    
Contract liabilities 2.2 2.2 1.1  
Contract liabilities recognized   0.4 $ 0.2  
Recognized revenue included in contract liabilities $ 0.1 0.2    
Interest received   $ 10.5    
Dominari Financial Heritage Strategies LLC [Member]        
Summary of Significant Accounting Policies [Line Items]        
Ownership interests       50.00%
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.2
Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Schedule of Gains and (Losses) on Marketable Securities [Abstract]        
Realized gain (loss) $ (30) $ 2,360 $ (1,414) $ 3,330
Unrealized gain (loss) 4,975 (2,353) 5,185 (2,940)
Dividend income 97 97 193 288
Total $ 5,042 $ 104 $ 3,964 $ 678
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.2
Long Term Equity Investments (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 27, 2025
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Long-Term Equity Investments [Line Items]              
Unrealized losses on long term investments   $ 31,700   $ 3,000 $ 32,000 $ 5,500  
Common shares percentage         80.00%    
Common shares outstanding percentage         80.00%    
Gross proceeds $ 220,000            
Common stock at a per share purchase price (in Dollars per share) $ 20 $ 0.0001     $ 0.0001   $ 0.0001
Carrying value         $ (32,000) $ 5,490  
Common Class B [Member]              
Long-Term Equity Investments [Line Items]              
Carrying value         32,000    
Common Class B [Member] | American Bitcoin [Member]              
Long-Term Equity Investments [Line Items]              
Carrying value         1,600    
Common Class A [Member]              
Long-Term Equity Investments [Line Items]              
Carrying value         $ 1,600    
Investment in Aeon Partners Fund Series DB (Databricks, Inc.) [Member]              
Long-Term Equity Investments [Line Items]              
Net proceeds     $ 500        
Investment gain amount     $ 28,000,000        
Investment in American Bitcoin Corp [Member]              
Long-Term Equity Investments [Line Items]              
Minority interest percentage   3.17%     3.17%    
Investment in American Bitcoin Corp [Member] | Private Placement [Member]              
Long-Term Equity Investments [Line Items]              
Minority interest percentage   2.60%     2.60%    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.2
Long Term Equity Investments - Schedule of Long Term Equity Investments (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis $ 10,799 $ 11,515
Long-term investments, Carrying Value 43,744 12,282
Investment In Kerna Health Inc [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 2,140 2,140
Long-term investments, Carrying Value 4,940 4,940
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 1,000 1,000
Long-term investments, Carrying Value [1] 1,000 1,000
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 170 170
Long-term investments, Carrying Value [1] 170 170
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [2] 597 597
Long-term investments, Carrying Value [2] 364 364
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 3,500 3,500
Long-term investments, Carrying Value [1] 2,248 2,248
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [2] 1,240 1,240
Long-term investments, Carrying Value [2] 1,240 1,240
Investment in Aeon Partners Fund Series DB (Databricks, Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 716
Long-term investments, Carrying Value [1] 538
Investment in Discord Inc. [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476 476
Long-term investments, Carrying Value 476 476
Investment in Thrasio, Inc. [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 300 300
Long-term investments, Carrying Value
Investment in Automation Anywhere, Inc. [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476 476
Long-term investments, Carrying Value 397 397
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 100 100
Long-term investments, Carrying Value [1] 109 109
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 25 25
Long-term investments, Carrying Value [1] 25 25
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 25 25
Long-term investments, Carrying Value [1] 25 25
Investment in AdvEn Inc. [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 750 750
Long-term investments, Carrying Value 750 750
Investment in American Bitcoin Corp [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis
Long-term investments, Carrying Value $ 32,000
[1] Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.
[2] Investments made in these companies are through both an SPV and direct investments.
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.25.2
Notes Receivable (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Mar. 24, 2025
Jun. 30, 2025
Dec. 31, 2024
Notes Receivable [Line Items]      
Maturity date   Dec. 31, 2025  
American Innovative Robotics, LLC [Member]      
Notes Receivable [Line Items]      
Interest income   $ 20,000  
Unrealized gain   221,000  
Note fully paid off $ 0    
Raefan Industries LLC [Member]      
Notes Receivable [Line Items]      
Note fully paid off   $ 0 $ 0
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.2
Notes Receivable - Schedule of Notes Receivable (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Notes receivable, at fair value    
Notes receivable, at fair value - current portion
Notes receivable, at fair value - non-current portion $ 902
Raefan Industries LLC [Member]    
Notes receivable, at fair value    
Maturity Date Jun. 30, 2025 Jun. 30, 2025
Stated Interest Rate 8.00% 8.00%
Principal Amount
Interest Receivable
Fair Value
American Innovative Robotics [Member]    
Notes receivable, at fair value    
Maturity Date Apr. 01, 2027 Apr. 01, 2027
Stated Interest Rate 8.00% 8.00%
Principal Amount $ 1,106
Interest Receivable 23
Fair Value $ 902
Convergent convertible note [Member]    
Notes receivable, at fair value    
Maturity Date   Dec. 02, 2024
Stated Interest Rate   8.00%
Principal Amount  
Interest Receivable  
Fair Value  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Jun. 30, 2024
Dec. 31, 2023
Marketable securities:        
Equities $ 18,772 $ 5,773    
Total marketable securities 18,772 5,773    
Notes receivable at fair value, current portion    
Notes receivable at fair value, non-current portion 902    
Quoted prices in active markets (Level 1) [Member]        
Marketable securities:        
Equities 11,700 4,156    
Total marketable securities 11,700 4,156    
Notes receivable at fair value, current portion    
Notes receivable at fair value, non-current portion    
Significant other observable inputs (Level 2) [Member]        
Marketable securities:        
Equities 7,072 1,617    
Total marketable securities    
Notes receivable at fair value, current portion    
Notes receivable at fair value, non-current portion    
Significant unobservable inputs (Level 3) [Member]        
Marketable securities:        
Equities    
Total marketable securities    
Notes receivable at fair value, current portion $ 964 $ 3,177
Notes receivable at fair value, non-current portion $ 902 $ 1,128 $ 1,129
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - Level 3 [Member] - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]    
Notes receivable at fair value, non-current Balance beginning $ 902 $ 1,129
Notes receivable at fair value, non-current Balance ending 1,128
Notes receivable at fair value, current Balance beginning 3,177
Collection of principal outstanding   (500)
Realized and unrealized gain and loss on note receivable, net   (1,657)
Unrealized gain (loss) on notes receivable 221 (1)
Change in interest receivable 20 (56)
Notes receivable at fair value, current Balance ending $ 964
Collection of principal and interest outstanding $ (1,143)  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.2
Leases (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jan. 11, 2023
Sep. 23, 2022
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Jul. 11, 2022
Leases [Abstract]              
Lease term   7 years         7 years
Lease rent expenses $ 12,874   $ 400 $ 200 $ 400 $ 200  
Increase rent amount   $ 51,868     $ 13,502    
Rent payment   $ 49,368          
Future minimum payments lease term     5 years   5 years    
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.2
Leases - Schedule of Lease Assets and Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Assets:          
Operating lease right-of-use-assets $ 2,733   $ 2,733   $ 2,944
Current          
Current Operating 418   418   410
Long-term          
Long-term Operating 2,442   2,442   $ 2,629
Total liabilities $ 2,860   $ 2,860    
Weighted-average remaining lease term - operating leases (in years) 5 years   5 years    
Weighted-average discount rate - operating leases 10.00%   10.00%    
Operating lease cost $ 178 $ 178 $ 357 $ 356  
Short-term lease rent expense 23 23 45 45  
Net rent expense $ 201 $ 201 402 $ 401  
Operating cash flows - operating leases     $ 324    
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.2
Leases - Schedule of Future Minimum Payments (Details)
$ in Thousands
Jun. 30, 2025
USD ($)
Schedule of Future Minimum Payments [Abstract]  
Remaining Period Ended December 31, 2025 $ 361
Year Ended December 31, 2026 685
Year Ended December 31, 2027 698
Year Ended December 31, 2028 766
Year Ended December 31, 2029 784
Thereafter 376
Total 3,670
Less present value discount (810)
Operating lease liabilities $ 2,860
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.2
Net Income (Loss) per Share - Schedule of Computation of Diluted Loss Per Share (Details) - shares
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Schedule of Computation of Diluted Loss Per Share [Line Items]    
Total diluted loss per share 17,914,109 476,023
Convertible preferred stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Line Items]    
Total diluted loss per share 34 34
Warrants to purchase common stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Line Items]    
Total diluted loss per share 7,517,421 444,796
Restricted stock awards [Member]    
Schedule of Computation of Diluted Loss Per Share [Line Items]    
Total diluted loss per share 50,000
Options to purchase common stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Line Items]    
Total diluted loss per share 10,346,654 31,193
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 11, 2025
Mar. 03, 2025
Feb. 18, 2025
Feb. 12, 2025
Feb. 10, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Oct. 07, 2022
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Common stock, shares issued           15,295,930   15,295,930   7,037,022  
Common stock, shares outstanding           15,235,782   15,235,782   6,976,874  
Price per share (in Dollars per share)         $ 3.47            
Net proceeds (in Dollars)         $ 13,500,000     $ 13,517,000    
Fair value of issued shares (in Dollars)           $ 2,339,000   13,517,000      
Additional common stock issuance           591,885          
Additional paid-in capital (in Dollars)           $ 2,300,000   $ 2,300,000      
Preferred stock, par value (in Dollars per share)           $ 0.0001   $ 0.0001   $ 0.0001  
Preferred stock, shares authorized           50,000,000   50,000,000   50,000,000  
Cash dividend per share payable (in Dollars per share)   $ 0.32                  
Cash dividends paid (in Dollars)               $ 7,000,000      
Treasury stock           60,148   60,148   60,148  
Granted shares               10,000,000      
Expense (in Dollars)               $ 26,100,000      
Share based compensation expense (in Dollars)               33,855,000 0    
Unrecognized stock-based compensation expense (in Dollars)           $ 25,000   25,000      
Estimated future stock-based compensation expense (in Dollars)               68,000      
Non-controlling interests (in Dollars)           1,050,000   1,050,000    
Series A Warrants [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Exercise price (in Dollars per share)         $ 3.72            
Term of warrants         5 years            
Series B Warrants [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Exercise price (in Dollars per share)         $ 4.22            
Term of warrants         5 years            
Equity Incentive Plan [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Common stock, shares issued         50,000            
Vested fair value (in Dollars)         $ 308,000            
Securities Purchase Agreements [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Number of shares issued         1,439,467            
Price per share (in Dollars per share)         $ 3.47            
Advisory Agreements [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Number of shares issued     850,000                
Fair value of issued shares (in Dollars)     $ 20,944,000                
Restricted Stock Awards [Member] | Equity Incentive Plan [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Option issued                     1,100,000
Stock Options [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Share based compensation expense (in Dollars)           26,198,600 $ 100,000        
Messr. Christopher Devall [Member] | Equity Incentive Plan [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Common stock, shares issued         351,851            
Vested fair value (in Dollars)         $ 2,100,000            
Messr. Anthony Hayes [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Vested fair value (in Dollars)       $ 3,400,000              
Granted shares       500,000              
Anthony Hayes And Kyle Wool [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Granted shares         5,000            
Common Stock [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Number of shares issued         2,436,587            
Share based compensation expense (in Dollars)           $ 12,000 $ 75,000 $ 7,657,000 $ 75,000    
Common Stock [Member] | Advisory Agreements [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Number of shares issued     2,550,000                
Common Stock [Member] | Anthony Hayes And Kyle Wool [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Vested fair value (in Dollars) $ 1,700,000                    
Granted shares 154,559                    
Series D Convertible Preferred Stock [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Preferred stock, shares issued           3,825   3,825   3,825  
Conversion of preferred stock           10   10      
Number of common stock issued upon conversion           1,373   1,373      
Preferred stock, shares authorized           5,000,000   5,000,000   5,000,000  
Preferred stock, shares outstanding           3,825   3,825   3,825  
Series D Convertible Preferred Stock [Member] | Stockholders [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Preferred stock, shares issued           1,379,685   1,379,685      
Preferred stock, par value (in Dollars per share)           $ 0.0001   $ 0.0001      
Series D-1 Convertible Preferred Stock [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Preferred stock, shares issued           834   834   834  
Preferred stock, par value (in Dollars per share)           $ 0.0001   $ 0.0001      
Conversion of preferred stock           10   10      
Number of common stock issued upon conversion           1,373   1,373      
Preferred stock, shares authorized           5,000,000   5,000,000      
Preferred stock, shares outstanding           834   834   834  
AV Manager [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Non-controlling interests           90.00%   90.00%      
AV Investment Manager [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Non-controlling interests           10.00%   10.00%      
Non-Controlling Interest [Member]                      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                      
Non-controlling interests           10.00%   10.00%      
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders’ Equity and Convertible Preferred Stock - Schedule of Assumptions Used in the Company’s Fair Value Analysis (Details)
6 Months Ended
Jun. 30, 2025
$ / shares
Schedule of Assumptions Used in the Company’s Fair Value Analysis [Abstract]  
Risk-free interest rate 4.14%
Estimated maturity date 10 years
Underlying stock price (in Dollars per share) $ 6.16
Expected volatility 112.50%
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders’ Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) - Warrant [Member]
6 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Schedule of Warrant Activity [Line Items]    
Granted, Warrants | shares   7,752,108
Granted, Weighted Average Exercise Price | $ / shares   $ 3.97
Granted, Total Intrinsic Value | $  
Expired, Warrants | shares   (87,598)
Expired, Weighted Average Exercise Price | $ / shares   $ 28.74
Expired, Total Intrinsic Value | $  
Exercised, Warrants | shares   (591,885)
Exercised, Weighted Average Exercise Price | $ / shares   $ 3.94
Exercised, Total Intrinsic Value | $  
Number of shares, ending balance | shares 444,796 7,517,421
Weighted Average per share, ending balance | $ / shares $ 29.25 $ 5.22
Outstanding ending balance, Total Intrinsic Value | $
Outstanding ending balance, Weighted Average Remaining Contractual Life 1 year 2 months 12 days 4 years 5 months 8 days
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders’ Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) - Restricted Stock [Member]
6 Months Ended
Jun. 30, 2025
$ / shares
shares
Schedule of Restricted Stock Awards Activity [Line Items]  
Number of shares, beginning balance | shares 50,000
Weighted Average per share, beginning balance | $ / shares $ 0.98
Number of shares, ending balance | shares 50,000
Weighted Average per share, ending balance | $ / shares $ 0.98
Number of Restricted Stock Awards, Granted | shares 1,210,969
Weighted Average Grant Day Fair Value, Granted | $ / shares $ 6.11
Number of Restricted Stock Awards, Vested | shares (1,210,969)
Weighted Average Grant Day Fair Value, Vested | $ / shares $ 2.2
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Day Fair Value, Forfeited | $ / shares
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders’ Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company’s Stock Option Plan (Details) - USD ($)
6 Months Ended
Dec. 31, 2024
Jun. 30, 2025
Schedule of Option Activity Under the Company’s Stock Option Plan [Abstract]    
Outstanding ending balance, Number of Shares 376,654 10,346,654
Outstanding ending balance, Weighted Average Exercise Price $ 4.29 $ 3.87
Outstanding ending balance, Total Intrinsic Value $ 123,633,000
Outstanding ending balance, Weighted Average Remaining Contractual Life (in years) 8 years 2 months 12 days 9 years 8 months 12 days
Options vested and exercisable, Number of Shares   10,212,604
Options vested and exercisable, Weighted Average Exercise Price   $ 3.87
Options vested and exercisable, Total Intrinsic Value   $ 74,615,000
Options vested and exercisable, Weighted Average Remaining Contractual Life (in years)   9 years 8 months 12 days
Employee options granted, Number of Shares   10,000,000
Employee options granted, Weighted Average Exercise Price   $ 3.85
Employee options granted, Total Intrinsic Value   9 years 9 months 18 days
Employee options expired, Number of Shares   (103,334)
Employee options expired, Weighted Average Exercise Price   $ 3.21
Employee options expired, Total Intrinsic Value  
Employee options forfeited, Number of Shares   (307,560)
Employee options forfeited, Weighted Average Exercise Price   $ 3.47
Employee options forfeited, Total Intrinsic Value   $ 47,267,000
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]        
Total revenue disaggregated $ 34,095 $ 6,174 $ 42,206 $ 7,541
Underwriting [Member]        
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]        
Total revenue disaggregated 14,954 4,057 20,560 4,723
Commissions [Member]        
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]        
Total revenue disaggregated 8,021 1,775 10,212 2,085
Account advisory and management fees [Member]        
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]        
Total revenue disaggregated 154 96 286 437
Carried interest fees [Member]        
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]        
Total revenue disaggregated 10,500 10,500
Other [Member]        
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]        
Total revenue disaggregated $ 466 $ 246 $ 648 $ 296
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.25.2
Regulatory (Details)
$ in Thousands
Jun. 30, 2025
USD ($)
Regulatory [Line Items]  
Net capital requirement $ 1,090
Excess amount 15,680
Dominari Securities [Member]  
Regulatory [Line Items]  
Net capital requirement $ 16,770
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.2
Related Party Transaction (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Related Party Transaction [Line Items]            
Revere’s outstanding equity percentage 30.00%          
Incurred fees   $ 310,405 $ 103,470 $ 318,405 $ 123,470  
Other current liabilities   65,000   65,000   $ 157,000
Employee loans           $ 2,400,000
Average annual interest rate           3.20%
Interest received       41,000    
Employee loans   1,870,000   1,870,000    
Management fee revenues       200,000    
Minimum [Member]            
Related Party Transaction [Line Items]            
Terms of loan agreements           3 years
Maximum [Member]            
Related Party Transaction [Line Items]            
Terms of loan agreements           7 years
Revere Securities, LLC [Member]            
Related Party Transaction [Line Items]            
Other current liabilities   $ 53,000   $ 53,000    
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Details)
6 Months Ended
Jun. 30, 2025
Segments
Segment Reporting [Abstract]  
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Chief Executive Officer
Reportable segments 2
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss (Details) - CODM [Member] - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]        
Revenue $ 34,095 $ 6,174 $ 42,206 $ 7,541
Operating Costs        
Compensation and benefits 50,292 6,687 85,987 8,836
Professional and consulting fees 1,206 461 2,627 1,418
Data processing 177 239 359 420
Other (income)/expenses 1,846 1,523 4,669 2,408
Loss from operations (19,426) (2,736) (51,436) (5,541)
Other (expenses) income        
Interest income 364 285 423 449
Gain on marketable securities 5,042 104 3,964 678
Unrealized loss on note receivable   (742) 221 (1,657)
Change in fair value of investments 31,680 (3,031) 32,000 (5,490)
Total other (expenses) income 37,086 (3,384) 36,608 (6,020)
Net loss 17,660 (6,120) (14,828) (11,561)
Noncontrolling interests 1,050   1,050  
Net gain attributable to common stock holders of Dominari Holdings 16,610   (15,878)  
Total assets 108,288 49,073 108,288 49,073
Dominari Financial [Member]        
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]        
Revenue 34,095 5,503 42,206 6,870
Operating Costs        
Compensation and benefits 30,540 4,962 37,430 6,384
Professional and consulting fees 711 293 1,358 761
Data processing 177 227 359 375
Other (income)/expenses (742) 847 733 1,370
Loss from operations 3,409 (826) 2,326 (2,020)
Other (expenses) income        
Interest income 364 205 381 341
Gain on marketable securities 4,236 3,326
Unrealized loss on note receivable  
Change in fair value of investments
Total other (expenses) income 4,600 205 3,707 341
Net loss 8,009 (621) 6,033 (1,679)
Noncontrolling interests 1,050   1,050  
Net gain attributable to common stock holders of Dominari Holdings 6,959   4,983  
Total assets 44,976 17,361 44,976 17,361
Legacy AIkido Pharma [Member]        
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]        
Revenue 671 671
Operating Costs        
Compensation and benefits 19,752 1,725 48,557 2,452
Professional and consulting fees 495 168 1,269 657
Data processing 12 45
Other (income)/expenses 2,588 676 3,936 1,038
Loss from operations (22,835) (1,910) (53,762) (3,521)
Other (expenses) income        
Interest income 80 42 108
Gain on marketable securities 806 104 638 678
Unrealized loss on note receivable   (742) 221 (1,657)
Change in fair value of investments 31,680 (3,031) 32,000 (5,490)
Total other (expenses) income 32,486 (3,589) 32,901 (6,361)
Net loss 9,651 (5,499) (20,861) (9,882)
Noncontrolling interests    
Net gain attributable to common stock holders of Dominari Holdings 9,651   (20,861)  
Total assets $ 63,312 $ 31,712 $ 63,312 $ 31,712
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.25.2
Income Taxes (Details) - USD ($)
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Income Taxes [Abstract]    
Income tax expense
Estimated annual effective tax rate  
XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 246 301 1 true 74 0 false 5 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Sheet http://www.aikidopharma.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - Organization and Description of Business and Recent Developments Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments Organization and Description of Business and Recent Developments Notes 7 false false R8.htm 995307 - Disclosure - Liquidity and Capital Resources Sheet http://www.aikidopharma.com/role/LiquidityandCapitalResources Liquidity and Capital Resources Notes 8 false false R9.htm 995308 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 995309 - Disclosure - Marketable Securities Sheet http://www.aikidopharma.com/role/MarketableSecurities Marketable Securities Notes 10 false false R11.htm 995310 - Disclosure - Long Term Equity Investments Sheet http://www.aikidopharma.com/role/LongTermEquityInvestments Long Term Equity Investments Notes 11 false false R12.htm 995311 - Disclosure - Notes Receivable Notes http://www.aikidopharma.com/role/NotesReceivable Notes Receivable Notes 12 false false R13.htm 995312 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities Fair Value of Financial Assets and Liabilities Notes 13 false false R14.htm 995313 - Disclosure - Leases Sheet http://www.aikidopharma.com/role/Leases Leases Notes 14 false false R15.htm 995314 - Disclosure - Net Income (Loss) per Share Sheet http://www.aikidopharma.com/role/NetIncomeLossperShare Net Income (Loss) per Share Notes 15 false false R16.htm 995315 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock Stockholders??? Equity and Convertible Preferred Stock Notes 16 false false R17.htm 995316 - Disclosure - Revenue Sheet http://www.aikidopharma.com/role/Revenue Revenue Notes 17 false false R18.htm 995317 - Disclosure - Commitments and Contingencies Sheet http://www.aikidopharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 995318 - Disclosure - Regulatory Sheet http://www.aikidopharma.com/role/Regulatory Regulatory Notes 19 false false R20.htm 995319 - Disclosure - Related Party Transaction Sheet http://www.aikidopharma.com/role/RelatedPartyTransaction Related Party Transaction Notes 20 false false R21.htm 995320 - Disclosure - Segment Reporting Sheet http://www.aikidopharma.com/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 995321 - Disclosure - Income Taxes Sheet http://www.aikidopharma.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.aikidopharma.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 996001 - Disclosure - Marketable Securities (Tables) Sheet http://www.aikidopharma.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.aikidopharma.com/role/MarketableSecurities 26 false false R27.htm 996002 - Disclosure - Long Term Equity Investments (Tables) Sheet http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables Long Term Equity Investments (Tables) Tables http://www.aikidopharma.com/role/LongTermEquityInvestments 27 false false R28.htm 996003 - Disclosure - Notes Receivable (Tables) Notes http://www.aikidopharma.com/role/NotesReceivableTables Notes Receivable (Tables) Tables http://www.aikidopharma.com/role/NotesReceivable 28 false false R29.htm 996004 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities 29 false false R30.htm 996005 - Disclosure - Leases (Tables) Sheet http://www.aikidopharma.com/role/LeasesTables Leases (Tables) Tables http://www.aikidopharma.com/role/Leases 30 false false R31.htm 996006 - Disclosure - Net Income (Loss) per Share (Tables) Sheet http://www.aikidopharma.com/role/NetIncomeLossperShareTables Net Income (Loss) per Share (Tables) Tables http://www.aikidopharma.com/role/NetIncomeLossperShare 31 false false R32.htm 996007 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Tables) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables Stockholders??? Equity and Convertible Preferred Stock (Tables) Tables http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock 32 false false R33.htm 996008 - Disclosure - Revenue (Tables) Sheet http://www.aikidopharma.com/role/RevenueTables Revenue (Tables) Tables http://www.aikidopharma.com/role/Revenue 33 false false R34.htm 996009 - Disclosure - Segment Reporting (Tables) Sheet http://www.aikidopharma.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.aikidopharma.com/role/SegmentReporting 34 false false R35.htm 996010 - Disclosure - Organization and Description of Business and Recent Developments (Details) Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails Organization and Description of Business and Recent Developments (Details) Details http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments 35 false false R36.htm 996011 - Disclosure - Liquidity and Capital Resources (Details) Sheet http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails Liquidity and Capital Resources (Details) Details http://www.aikidopharma.com/role/LiquidityandCapitalResources 36 false false R37.htm 996012 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 37 false false R38.htm 996013 - Disclosure - Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) Sheet http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) Details 38 false false R39.htm 996014 - Disclosure - Long Term Equity Investments (Details) Sheet http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails Long Term Equity Investments (Details) Details http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables 39 false false R40.htm 996015 - Disclosure - Long Term Equity Investments - Schedule of Long Term Equity Investments (Details) Sheet http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable Long Term Equity Investments - Schedule of Long Term Equity Investments (Details) Details 40 false false R41.htm 996016 - Disclosure - Notes Receivable (Details) Notes http://www.aikidopharma.com/role/NotesReceivableDetails Notes Receivable (Details) Details http://www.aikidopharma.com/role/NotesReceivableTables 41 false false R42.htm 996017 - Disclosure - Notes Receivable - Schedule of Notes Receivable (Details) Notes http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable Notes Receivable - Schedule of Notes Receivable (Details) Details 42 false false R43.htm 996018 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) Sheet http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) Details 43 false false R44.htm 996019 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Details 44 false false R45.htm 996020 - Disclosure - Leases (Details) Sheet http://www.aikidopharma.com/role/LeasesDetails Leases (Details) Details http://www.aikidopharma.com/role/LeasesTables 45 false false R46.htm 996021 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details) Sheet http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable Leases - Schedule of Lease Assets and Liabilities (Details) Details 46 false false R47.htm 996022 - Disclosure - Leases - Schedule of Future Minimum Payments (Details) Sheet http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable Leases - Schedule of Future Minimum Payments (Details) Details 47 false false R48.htm 996023 - Disclosure - Net Income (Loss) per Share - Schedule of Computation of Diluted Loss Per Share (Details) Sheet http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable Net Income (Loss) per Share - Schedule of Computation of Diluted Loss Per Share (Details) Details http://www.aikidopharma.com/role/NetIncomeLossperShareTables 48 false false R49.htm 996024 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails Stockholders??? Equity and Convertible Preferred Stock (Details) Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 49 false false R50.htm 996025 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock - Schedule of Assumptions Used in the Company???s Fair Value Analysis (Details) Sheet http://www.aikidopharma.com/role/ScheduleofAssumptionsUsedintheCompanysFairValueAnalysisTable Stockholders??? Equity and Convertible Preferred Stock - Schedule of Assumptions Used in the Company???s Fair Value Analysis (Details) Details 50 false false R51.htm 996026 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) Sheet http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable Stockholders??? Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) Details 51 false false R52.htm 996027 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) Sheet http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable Stockholders??? Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) Details 52 false false R53.htm 996028 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company???s Stock Option Plan (Details) Sheet http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable Stockholders??? Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company???s Stock Option Plan (Details) Details 53 false false R54.htm 996029 - Disclosure - Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) Sheet http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) Details 54 false false R55.htm 996030 - Disclosure - Regulatory (Details) Sheet http://www.aikidopharma.com/role/RegulatoryDetails Regulatory (Details) Details http://www.aikidopharma.com/role/Regulatory 55 false false R56.htm 996031 - Disclosure - Related Party Transaction (Details) Sheet http://www.aikidopharma.com/role/RelatedPartyTransactionDetails Related Party Transaction (Details) Details http://www.aikidopharma.com/role/RelatedPartyTransaction 56 false false R57.htm 996032 - Disclosure - Segment Reporting (Details) Sheet http://www.aikidopharma.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.aikidopharma.com/role/SegmentReportingTables 57 false false R58.htm 996033 - Disclosure - Segment Reporting - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss (Details) Sheet http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable Segment Reporting - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss (Details) Details 58 false false R59.htm 996034 - Disclosure - Income Taxes (Details) Sheet http://www.aikidopharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.aikidopharma.com/role/IncomeTaxes 59 false false All Reports Book All Reports domh-20250630.xsd domh-20250630_cal.xml domh-20250630_def.xml domh-20250630_lab.xml domh-20250630_pre.xml ea0252311-10q_dominari.htm http://fasb.org/us-gaap/2025 http://xbrl.sec.gov/dei/2025 http://xbrl.sec.gov/ecd/2025 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0252311-10q_dominari.htm": { "nsprefix": "domh", "nsuri": "http://www.aikidopharma.com/20250630", "dts": { "schema": { "local": [ "domh-20250630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd", "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "domh-20250630_cal.xml" ] }, "definitionLink": { "local": [ "domh-20250630_def.xml" ] }, "labelLink": { "local": [ "domh-20250630_lab.xml" ] }, "presentationLink": { "local": [ "domh-20250630_pre.xml" ] }, "inline": { "local": [ "ea0252311-10q_dominari.htm" ] } }, "keyStandard": 271, "keyCustom": 30, "axisStandard": 18, "axisCustom": 0, "memberStandard": 22, "memberCustom": 47, "hidden": { "total": 171, "http://fasb.org/us-gaap/2025": 157, "http://www.aikidopharma.com/20250630": 10, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 246, "entityCount": 1, "segmentCount": 74, "elementCount": 717, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 976, "http://xbrl.sec.gov/dei/2025": 30, "http://xbrl.sec.gov/ecd/2025": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ReceivablesFromBrokersDealersAndClearingOrganizations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R3": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R4": { "role": "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c72", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c72", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R7": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments", "longName": "995306 - Disclosure - Organization and Description of Business and Recent Developments", "shortName": "Organization and Description of Business and Recent Developments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.aikidopharma.com/role/LiquidityandCapitalResources", "longName": "995307 - Disclosure - Liquidity and Capital Resources", "shortName": "Liquidity and Capital Resources", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "995308 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.aikidopharma.com/role/MarketableSecurities", "longName": "995309 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestments", "longName": "995310 - Disclosure - Long Term Equity Investments", "shortName": "Long Term Equity Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.aikidopharma.com/role/NotesReceivable", "longName": "995311 - Disclosure - Notes Receivable", "shortName": "Notes Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities", "longName": "995312 - Disclosure - Fair Value of Financial Assets and Liabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.aikidopharma.com/role/Leases", "longName": "995313 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.aikidopharma.com/role/NetIncomeLossperShare", "longName": "995314 - Disclosure - Net Income (Loss) per Share", "shortName": "Net Income (Loss) per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock", "longName": "995315 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.aikidopharma.com/role/Revenue", "longName": "995316 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.aikidopharma.com/role/CommitmentsandContingencies", "longName": "995317 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.aikidopharma.com/role/Regulatory", "longName": "995318 - Disclosure - Regulatory", "shortName": "Regulatory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransaction", "longName": "995319 - Disclosure - Related Party Transaction", "shortName": "Related Party Transaction", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.aikidopharma.com/role/SegmentReporting", "longName": "995320 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.aikidopharma.com/role/IncomeTaxes", "longName": "995321 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c8", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.aikidopharma.com/role/MarketableSecuritiesTables", "longName": "996001 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables", "longName": "996002 - Disclosure - Long Term Equity Investments (Tables)", "shortName": "Long Term Equity Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.aikidopharma.com/role/NotesReceivableTables", "longName": "996003 - Disclosure - Notes Receivable (Tables)", "shortName": "Notes Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables", "longName": "996004 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.aikidopharma.com/role/LeasesTables", "longName": "996005 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.aikidopharma.com/role/NetIncomeLossperShareTables", "longName": "996006 - Disclosure - Net Income (Loss) per Share (Tables)", "shortName": "Net Income (Loss) per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables", "longName": "996007 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.aikidopharma.com/role/RevenueTables", "longName": "996008 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.aikidopharma.com/role/SegmentReportingTables", "longName": "996009 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "longName": "996010 - Disclosure - Organization and Description of Business and Recent Developments (Details)", "shortName": "Organization and Description of Business and Recent Developments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c86", "name": "us-gaap:InvestmentCompanyFeePaidIndirectly", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c86", "name": "us-gaap:InvestmentCompanyFeePaidIndirectly", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails", "longName": "996011 - Disclosure - Liquidity and Capital Resources (Details)", "shortName": "Liquidity and Capital Resources (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ReceivablesFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LiquidationBasisOfAccountingTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R37": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996012 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R38": { "role": "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable", "longName": "996013 - Disclosure - Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details)", "shortName": "Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:RealizedInvestmentGainsLosses", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:RealizedInvestmentGainsLosses", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "longName": "996014 - Disclosure - Long Term Equity Investments (Details)", "shortName": "Long Term Equity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:PaymentsToAcquireLongtermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:PaymentsToAcquireLongtermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable", "longName": "996015 - Disclosure - Long Term Equity Investments - Schedule of Long Term Equity Investments (Details)", "shortName": "Long Term Equity Investments - Schedule of Long Term Equity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.aikidopharma.com/role/NotesReceivableDetails", "longName": "996016 - Disclosure - Notes Receivable (Details)", "shortName": "Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c2", "name": "domh:MaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "domh:MaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable", "longName": "996017 - Disclosure - Notes Receivable - Schedule of Notes Receivable (Details)", "shortName": "Notes Receivable - Schedule of Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:NotesAndLoansReceivableNetNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c134", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R43": { "role": "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "longName": "996018 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details)", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable", "longName": "996019 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c148", "name": "us-gaap:NotesAndLoansReceivableNetNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c151", "name": "domh:CollectionOfPrincipalOutstanding", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R45": { "role": "http://www.aikidopharma.com/role/LeasesDetails", "longName": "996020 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c155", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c155", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable", "longName": "996021 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details)", "shortName": "Leases - Schedule of Lease Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R47": { "role": "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "longName": "996022 - Disclosure - Leases - Schedule of Future Minimum Payments (Details)", "shortName": "Leases - Schedule of Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "longName": "996023 - Disclosure - Net Income (Loss) per Share - Schedule of Computation of Diluted Loss Per Share (Details)", "shortName": "Net Income (Loss) per Share - Schedule of Computation of Diluted Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "longName": "996024 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c168", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "unique": true } }, "R50": { "role": "http://www.aikidopharma.com/role/ScheduleofAssumptionsUsedintheCompanysFairValueAnalysisTable", "longName": "996025 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Assumptions Used in the Company\u2019s Fair Value Analysis (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Assumptions Used in the Company\u2019s Fair Value Analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "longName": "996026 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c197", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c197", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "longName": "996027 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c199", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c199", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable", "longName": "996028 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company\u2019s Stock Option Plan (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company\u2019s Stock Option Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable", "longName": "996029 - Disclosure - Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details)", "shortName": "Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.aikidopharma.com/role/RegulatoryDetails", "longName": "996030 - Disclosure - Regulatory (Details)", "shortName": "Regulatory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c2", "name": "domh:NetCapitalAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "domh:NetCapitalAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails", "longName": "996031 - Disclosure - Related Party Transaction (Details)", "shortName": "Related Party Transaction (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c224", "name": "us-gaap:RelatedPartyTransactionRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c224", "name": "us-gaap:RelatedPartyTransactionRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.aikidopharma.com/role/SegmentReportingDetails", "longName": "996032 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable", "longName": "996033 - Disclosure - Segment Reporting - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss (Details)", "shortName": "Segment Reporting - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c230", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c230", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0252311-10q_dominari.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.aikidopharma.com/role/IncomeTaxesDetails", "longName": "996034 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": null, "uniqueAnchor": null } }, "tag": { "domh_AVInvestmentManagerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AVInvestmentManagerMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AV Investment Manager [Member]", "label": "AVInvestment Manager Member" } } }, "auth_ref": [] }, "domh_AVManagerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AVManagerMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AV Manager [Member]", "label": "AVManager Member" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Notes Receivable [Line Items]", "terseLabel": "Notes Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r192", "r957" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r30", "r31" ] }, "us-gaap_AccruedRentCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedRentCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent payment", "label": "Accrued Rent", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements." } } }, "auth_ref": [ "r31", "r35", "r70" ] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions", "label": "Accrued Sales Commission, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31", "r708" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r844" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r41", "r772", "r1057" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r529", "r942", "r943", "r944", "r945", "r1014", "r1060" ] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r900" ] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r900" ] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r898" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r857" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [ "r974", "r977" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:", "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]" } } }, "auth_ref": [] }, "domh_AdvisoryAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AdvisoryAgreementsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory Agreements [Member]", "label": "Advisory Agreements Member" } } }, "auth_ref": [] }, "domh_AdvisoryFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AdvisoryFeesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Account advisory and management fees [Member]", "label": "Advisory Fees Member" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r891" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r807", "r818", "r834", "r869" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r810", "r821", "r837", "r872" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r892" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r857" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r864" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r811", "r822", "r838", "r864", "r873", "r877", "r885" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r883" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r336", "r340", "r341" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated future stock-based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [ "r1006" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "domh_AmericanBitcoinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AmericanBitcoinMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Bitcoin [Member]", "label": "American Bitcoin Member" } } }, "auth_ref": [] }, "domh_AmericanInnovativeRoboticsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AmericanInnovativeRoboticsLLCMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Innovative Robotics, LLC [Member]", "label": "American Innovative Robotics LLCMember" } } }, "auth_ref": [] }, "domh_AmericanInnovativeRoboticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AmericanInnovativeRoboticsMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "American Innovative Robotics [Member]", "label": "American Innovative Robotics Member" } } }, "auth_ref": [] }, "domh_AmericanVenturesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AmericanVenturesLLCMember", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Ventures LLC [Member]", "label": "American Ventures LLCMember" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r814" ] }, "domh_AnthonyHayesAndKyleWoolMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AnthonyHayesAndKyleWoolMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anthony Hayes And Kyle Wool [Member]", "label": "Anthony Hayes And Kyle Wool Member" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total diluted loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r154" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r154" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Computation of Diluted Loss Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r154" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r154" ] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r366" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r68", "r80", "r101", "r122", "r123", "r124", "r158", "r171", "r181", "r184", "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r368", "r372", "r419", "r467", "r468", "r481", "r572", "r725", "r726", "r738", "r772", "r774", "r775", "r786", "r969", "r970", "r1035" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r97", "r108", "r122", "r123", "r124", "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r368", "r372", "r419", "r772", "r969", "r970", "r1035" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r814" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r799", "r802", "r814" ] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r799", "r802", "r814" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r799", "r802", "r814" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r896" ] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "domh_AverageAnnualInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "AverageAnnualInterestRate", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average annual interest rate", "documentation": "Average annual interest rate.", "label": "Average Annual Interest Rate" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r880" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r881" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r876" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r332", "r333", "r334", "r335" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r879" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r878" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r877" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r877" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r934" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r802", "r814" ] }, "domh_CarriedInterestFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "CarriedInterestFeesMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Carried interest fees [Member]", "label": "Carried Interest Fees Member" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r82", "r483", "r541", "r566", "r772", "r774", "r775", "r786", "r916" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Liquidity and Capital Resources [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalent", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r14", "r99", "r706" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r14", "r56", "r119" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation", "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r56" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquid insured deposits", "label": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "domh_ChangeInFairValueOfLongtermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ChangeInFairValueOfLongtermInvestment", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in carrying value of long-term investment", "verboseLabel": "Carrying value", "documentation": "Change in fair value of long-term investment.", "label": "Change In Fair Value Of Longterm Investment" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r855" ] }, "domh_ChiefOperatingDecisionMakerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ChiefOperatingDecisionMakerMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "CODM [Member]", "label": "Chief Operating Decision Maker Member" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r852" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r850" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r87", "r104", "r105", "r106", "r122", "r124", "r148", "r149", "r151", "r153", "r160", "r161", "r198", "r211", "r213", "r214", "r215", "r218", "r219", "r238", "r239", "r241", "r242", "r244", "r247", "r250", "r251", "r255", "r258", "r266", "r419", "r517", "r518", "r519", "r520", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r542", "r558", "r580", "r603", "r685", "r686", "r687", "r688", "r689", "r909", "r937", "r939", "r946" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]", "terseLabel": "Stockholders\u2019 Equity and Convertible Preferred Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r104", "r105", "r106", "r160", "r241", "r250", "r251", "r253", "r255", "r258", "r264", "r266", "r378", "r517", "r518", "r519", "r520", "r739", "r909", "r935", "r937" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r975" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r122", "r126", "r267" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Activity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r975" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r856" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r856" ] }, "domh_CollectionOfPrincipalAndInterestOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "CollectionOfPrincipalAndInterestOutstanding", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of principal and interest outstanding", "documentation": "The amount of collection of principal and interest outstanding.", "label": "Collection Of Principal And Interest Outstanding" } } }, "auth_ref": [] }, "domh_CollectionOfPrincipalOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "CollectionOfPrincipalOutstanding", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of principal outstanding", "documentation": "Amount of collection of principal outstanding.", "label": "Collection Of Principal Outstanding" } } }, "auth_ref": [] }, "us-gaap_CommissionsAndFloorBrokerageReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommissionsAndFloorBrokerageReceivables", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions receivable", "label": "Commissions and Floor Brokerage Receivables", "documentation": "Amount receivable from broker-dealers from commissions for executing orders on the floor of an exchange." } } }, "auth_ref": [ "r921", "r1043" ] }, "domh_CommissionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "CommissionsMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions [Member]", "label": "Commissions Member" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r59", "r205", "r206", "r700", "r963", "r968" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonClassAMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A [Member]", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1060" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonClassBMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class B [Member]", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1060" ] }, "domh_CommonSharesOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "CommonSharesOutstandingPercentage", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares outstanding percentage", "documentation": "Common shares outstanding percentage.", "label": "Common Shares Outstanding Percentage" } } }, "auth_ref": [] }, "domh_CommonSharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "CommonSharesPercentage", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares percentage", "documentation": "Common shares percentage.", "label": "Common Shares Percentage" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividend per share payable (in Dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r62" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r776", "r777", "r778", "r780", "r781", "r782", "r783", "r942", "r943", "r945", "r1014", "r1050", "r1060" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common stock at a per share purchase price (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r39", "r558" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r39", "r558", "r578", "r1060", "r1061" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value, 100,000,000 shares authorized\u037e 15,295,930 and 7,037,022 shares issued as of June 30, 2025 and December 31, 2024, respectively\u037e 15,235,782 and 6,976,874 shares outstanding as of June 30, 2025 and December 31, 2024", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r39", "r239", "r246", "r485", "r772" ] }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStocksIncludingAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital (in Dollars)", "label": "Common Stocks, Including Additional Paid in Capital", "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued." } } }, "auth_ref": [ "r39", "r41", "r62" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r861" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r860" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r862" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r859" ] }, "us-gaap_ComplianceWithRegulatoryCapitalRequirementsForMortgageCompaniesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComplianceWithRegulatoryCapitalRequirementsForMortgageCompaniesLineItems", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Regulatory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r692", "r693", "r694", "r695" ] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r802" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r269", "r270", "r272", "r291" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities \u2013 current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r269", "r270", "r272", "r291" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities, less current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r269", "r270", "r272", "r291" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r292" ] }, "domh_ConvergentConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ConvergentConvertibleNoteMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convergent convertible note [Member]", "label": "Convergent Convertible Note Member" } } }, "auth_ref": [] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible preferred stock [Member]", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r250", "r251", "r255", "r780", "r781", "r782", "r783" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of preferred stock", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r10", "r20", "r38", "r61", "r261" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "domh_DataProcessing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "DataProcessing", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Data processing", "documentation": "The amount of data processing.", "label": "Data Processing" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r9", "r30", "r31", "r69", "r71", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r733", "r734", "r735", "r736", "r737", "r770", "r935", "r936", "r938", "r941", "r964", "r965", "r966", "r1025", "r1026", "r1047" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stated Interest Rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r33", "r221" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r517" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r103", "r733", "r1018", "r1019" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r9", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r733", "r734", "r735", "r736", "r737", "r770", "r935", "r936", "r938", "r941", "r964", "r965", "r966", "r1025", "r1026", "r1047" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terms of loan agreements", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note fully paid off", "label": "Debt Securities, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r498", "r926", "r927" ] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r826", "r827", "r841" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r19", "r116", "r709", "r710", "r712", "r714" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r289", "r290", "r740", "r741", "r742", "r743", "r744", "r745", "r746" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r289", "r290", "r740", "r741", "r742", "r743", "r744", "r745", "r746" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenue Disaggregated by Revenue Type", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r976" ] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used in the Company\u2019s Fair Value Analysis", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r978" ] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r826", "r827", "r841" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends Issued", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r2", "r62" ] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsCash", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends paid (in Dollars)", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": [ "r2", "r62" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r802" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r799", "r802", "r814" ] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentCopyrightInformation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentCreationDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentEffectiveDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r799", "r802", "r814", "r865" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r799", "r802", "r814", "r865" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationDocumentAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r800" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r788" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r802" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r802" ] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentSubtitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentSynopsis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r842" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentVersion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r791" ] }, "domh_DominariFinancialHeritageStrategiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "DominariFinancialHeritageStrategiesLLCMember", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Financial Heritage Strategies LLC [Member]", "label": "Dominari Financial Heritage Strategies LLCMember" } } }, "auth_ref": [] }, "domh_DominariFinancialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "DominariFinancialMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Financial [Member]", "label": "Dominari Financial Member" } } }, "auth_ref": [] }, "domh_DominariSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "DominariSecuritiesMember", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Securities [Member]", "label": "Dominari Securities Member" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r854" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) per Share [Abstract]", "terseLabel": "Net income (loss) per share, basic and diluted" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r92", "r115", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r146", "r148", "r151", "r152", "r153", "r157", "r237", "r339", "r362", "r365", "r391", "r392", "r466", "r495", "r716" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted\t(in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r92", "r115", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r148", "r151", "r152", "r153", "r157", "r237", "r339", "r362", "r365", "r391", "r392", "r466", "r495", "r716" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NetIncomeLossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r145", "r154", "r155", "r156" ] }, "domh_EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of new accounting pronouncements to be adopted in future periods", "documentation": "Effect of new accounting pronouncements to be adopted in future periods.", "label": "Effect Of New Accounting Pronouncements To Be Adopted In Future Periods Policy Text Block" } } }, "auth_ref": [] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r904" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r345", "r753" ] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r904" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r905" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r904" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r905" ] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r903" ] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r905" ] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r907" ] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [ "r924" ] }, "domh_EmployeeLoansOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "EmployeeLoansOutstanding", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee loans", "documentation": "The amount of outstanding employee loans.", "label": "Employee Loans Outstanding" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r337" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase common stock [Member]", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock Options [Member]", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005" ] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitiesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r790" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r794" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r790" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityContactPersonnelLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r790" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r906" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r790" ] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityHomeCountryISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r895" ] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r894" ] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityLegalForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingDepositoryReceiptRatio", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingForeign", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingParValuePerShare", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingPrimary", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingSecurityTradingCurrency", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityNumberOfEmployees", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r814" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r790" ] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityReportingCurrencyISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r790" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r790" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r790" ] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r897" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r848" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r890" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r890" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r890" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r89", "r91", "r92", "r111", "r112", "r113", "r129", "r130", "r131", "r133", "r140", "r142", "r144", "r159", "r199", "r200", "r201", "r236", "r268", "r339", "r351", "r352", "r359", "r360", "r361", "r363", "r364", "r365", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r433", "r447", "r494", "r504", "r505", "r506", "r529", "r603" ] }, "domh_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "EquityIncentivePlanMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plan [Member]", "label": "Equity Incentive Plan Member" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r195", "r196", "r197", "r358", "r419", "r910", "r911", "r912", "r1008", "r1009", "r1010", "r1011" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interests", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r195", "r419" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Equities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r102", "r417", "r707" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r858" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r807", "r818", "r834", "r869" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r804", "r815", "r831", "r866" ] }, "us-gaap_ExcessCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ExcessCapital", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess amount", "label": "Banking Regulation, Total Risk-Based Capital, Excess, Actual", "documentation": "Amount of total risk-based capital exceeding minimum required for capital adequacy as defined by regulatory framework." } } }, "auth_ref": [ "r474" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExchangeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r864" ] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r902" ] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r902" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "domh_FPSPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "FPSPurchaseAgreementMember", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FPS Purchase Agreement [Member]", "label": "FPSPurchase Agreement Member" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 }, "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of investments", "negatedTerseLabel": "Change in fair value of investments", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r4" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Assets and Liabilities that are Measured at Fair Value [Line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r394", "r395", "r408", "r763" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r228", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r393", "r395", "r396", "r397", "r398", "r407", "r408", "r410", "r418", "r455", "r456", "r457", "r705", "r734", "r735", "r747", "r748", "r749", "r750", "r751", "r763", "r765", "r769" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Assets and Liabilities", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r396", "r403", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r414", "r464", "r763", "r766" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets (Level 1) [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r228", "r295", "r300", "r302", "r395", "r408", "r418", "r455", "r705", "r747", "r748", "r749", "r750", "r751", "r763", "r769" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2) [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r228", "r295", "r300", "r302", "r304", "r395", "r396", "r408", "r418", "r456", "r705", "r734", "r735", "r747", "r748", "r749", "r750", "r751", "r763", "r769" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3) [Member]", "verboseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r228", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r395", "r396", "r397", "r398", "r408", "r418", "r457", "r705", "r734", "r735", "r747", "r748", "r749", "r750", "r751", "r763", "r765", "r769" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r228", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r393", "r395", "r396", "r397", "r398", "r407", "r408", "r410", "r418", "r455", "r456", "r457", "r705", "r734", "r735", "r747", "r748", "r749", "r750", "r751", "r763", "r765", "r769" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r409" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r399", "r404", "r409" ] }, "domh_FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_FeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FeeIncome", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fee revenues", "label": "Fee Income", "documentation": "Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees." } } }, "auth_ref": [ "r1059" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r811", "r822", "r838", "r873" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r811", "r822", "r838", "r873" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r811", "r822", "r838", "r873" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r811", "r822", "r838", "r873" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r811", "r822", "r838", "r873" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "FormerAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r801", "r825" ] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "FormerFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r853" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Realized and unrealized gain and loss on note receivable, net", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r52", "r54", "r908" ] }, "us-gaap_GainLossOnSaleOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnSaleOfNotesReceivable", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Realized and unrealized gain (loss) on note receivable, net", "negatedLabel": "Realized and unrealized (gain) loss on note receivable", "label": "Gain (Loss) on Sale of Financing Receivable", "documentation": "Amount of gain (loss) on sale of financing receivable." } } }, "auth_ref": [ "r459" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r48", "r582" ] }, "us-gaap_GoodFaithAndMarginDepositsWithBrokerDealers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodFaithAndMarginDepositsWithBrokerDealers", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Good faith deposits", "label": "Good Faith and Margin Deposit with Broker-Dealer", "documentation": "Amount of right to receive cash and securities on deposit with broker-dealers to demonstrate an intention to complete a purchase (good faith deposit) and collateral deposited by counterparty to cover the credit risk assumed (margin deposit)." } } }, "auth_ref": [ "r917" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r799", "r802", "r814" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r202", "r203", "r204", "r374", "r375", "r376", "r377", "r400", "r404", "r409", "r420", "r421", "r422", "r501", "r503", "r588", "r703", "r705", "r754", "r755", "r761", "r762", "r764", "r769", "r1012", "r1013", "r1049" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r203", "r204", "r374", "r375", "r376", "r377", "r400", "r404", "r409", "r420", "r421", "r422", "r501", "r503", "r588", "r703", "r705", "r754", "r755", "r761", "r762", "r764", "r769", "r1012", "r1013", "r1049" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r122", "r125", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r355", "r356", "r357", "r480", "r510", "r523", "r753" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r81", "r85", "r122", "r143", "r144", "r158", "r175", "r184", "r344", "r345", "r354", "r499", "r711", "r713", "r715", "r753" ] }, "domh_IncreaseDecreaseInAccruedCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "IncreaseDecreaseInAccruedCommissions", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions", "documentation": "Increase decrease in accrued commissions.", "label": "Increase Decrease In Accrued Commissions" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r462", "r932" ] }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivable from clearing brokers", "label": "Increase (Decrease) in Deposit Assets", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } }, "auth_ref": [ "r3" ] }, "domh_IncreaseDecreaseInInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "IncreaseDecreaseInInterestReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in interest receivable", "documentation": "The amount of change in interest receivable noncurrent.", "label": "Increase Decrease In Interest Receivable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInNotesReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInNotesReceivables", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Notes receivable, at fair value - net interest accrued", "label": "Increase (Decrease) in Notes Receivables", "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r913", "r932" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued salaries and benefits", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r932" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInPrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidRent", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase rent amount", "label": "Increase (Decrease) in Prepaid Rent", "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods." } } }, "auth_ref": [ "r3" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r811", "r822", "r838", "r864", "r873", "r877", "r885" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r883" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r803", "r889" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r803", "r889" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r803", "r889" ] }, "us-gaap_InterestAndFeeIncomeOtherLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestAndFeeIncomeOtherLoans", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions receivable", "label": "Interest and Fee Income, Other Loans", "documentation": "Amount of interest and fee income from loans classified as other." } } }, "auth_ref": [ "r74" ] }, "domh_InterestCarried": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InterestCarried", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "documentation": "Interest carried.", "label": "Interest Carried" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestIncomeOther", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [ "r713" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r921", "r1062" ] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r827", "r828", "r829", "r830" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r843" ] }, "us-gaap_InvestmentCompanyFeePaidIndirectly": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentCompanyFeePaidIndirectly", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional seller paid (in Dollars)", "label": "Investment Company, Fee Paid Indirectly", "documentation": "Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction." } } }, "auth_ref": [ "r521", "r582", "r583", "r584", "r585", "r588" ] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r843" ] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r843" ] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long Term Equity Investments", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": [ "r1051", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "domh_InvestmentInAdvEnIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInAdvEnIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in AdvEn Inc. [Member]", "label": "Investment In Adv En Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Aeon Partners Fund Series DB (Databricks, Inc.) [Member]", "label": "Investment In Aeon Partners Fund Series DBDatabricks Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Aeon Partners Fund Series EG (Epic Games, Inc.) [Member]", "label": "Investment In Aeon Partners Fund Series EGEpic Games Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInAmericanBitcoinCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInAmericanBitcoinCorpMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in American Bitcoin Corp [Member]", "label": "Investment In American Bitcoin Corp Member" } } }, "auth_ref": [] }, "domh_InvestmentInAutomationAnywhereIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInAutomationAnywhereIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Automation Anywhere, Inc. [Member]", "label": "Investment In Automation Anywhere Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInDiscordIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInDiscordIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Discord Inc. [Member]", "label": "Investment In Discord Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI) [Member]", "label": "Investment In Dominari Master SPVLLCSeries VIXAICorp Dba XAIMember" } } }, "auth_ref": [] }, "domh_InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.) [Member]", "label": "Investment In Dominari Master SPVLLCSeries XICerebras Systems Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Dominari Master SPV LLC Series XII (Groq, Inc.) [Member]", "label": "Investment In Dominari Master SPVLLCSeries XIIGroq Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInKernaHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInKernaHealthIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment In Kerna Health Inc [Member]", "label": "Investment In Kerna Health Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass) [Member]", "label": "Investment In MWLSVMaster Class LLCYanka Industries Inc Dba Masterclass Member" } } }, "auth_ref": [] }, "domh_InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken) [Member]", "label": "Investment In Payward Inc And MWSIVCKraken IILLCPayward Inc Dba Kraken Member" } } }, "auth_ref": [] }, "domh_InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd) [Member]", "label": "Investment In Revere Master SPVSeries1 Qxpress Pte Ltd Member" } } }, "auth_ref": [] }, "domh_InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) [Member]", "label": "Investment In Tesspay Inc And Revere Master SPVSeries VITess Pay Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInThrasioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "InvestmentInThrasioIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Thrasio, Inc. [Member]", "label": "Investment In Thrasio Inc Member" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r158", "r174", "r184", "r725", "r925" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, Cost Basis", "label": "Investment Owned, Cost", "documentation": "Cost of the investment." } } }, "auth_ref": [ "r513", "r546", "r547", "r624", "r634", "r650", "r676", "r778", "r786", "r1054" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term equity investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r497", "r513", "r514", "r515", "r516", "r631", "r633" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Long Term Equity Investments", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r914", "r915", "r958" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r543", "r544", "r545", "r546", "r548", "r611", "r620", "r636", "r644", "r657", "r662", "r677", "r681", "r682", "r683", "r684", "r778" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r543", "r544", "r545", "r546", "r548", "r611", "r620", "r636", "r644", "r657", "r662", "r677", "r681", "r682", "r683", "r684", "r778" ] }, "us-gaap_InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Long Term Equity Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/MarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r76", "r88", "r193", "r194", "r415", "r416", "r1046" ] }, "domh_JointVenturesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "JointVenturesPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Ventures", "documentation": "Disclosure of accounting policy for joint ventures.", "label": "Joint Ventures Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Net rent expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r438", "r771" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Assets and Liabilities", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "domh_LegacyAIkidoPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "LegacyAIkidoPharmaMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy AIkido Pharma [Member]", "label": "Legacy AIkido Pharma Member" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityIdentifier", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": [ "r787" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r437" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r444", "r936", "r941", "r1047" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444", "r936", "r941", "r1047" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444", "r936", "r941", "r1047" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444", "r936", "r941", "r1047" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444", "r936", "r941", "r1047" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444", "r936", "r941", "r1047" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Period Ended December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r444" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future minimum payments lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r446", "r1028" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1029" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r432" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r9", "r30", "r31", "r32", "r34", "r35", "r36", "r37", "r122", "r123", "r124", "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r369", "r372", "r373", "r419", "r557", "r718", "r738", "r786", "r969", "r1035", "r1036" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r45", "r73", "r488", "r772", "r774", "r775", "r935", "r940", "r960", "r1024" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r32", "r98", "r122", "r123", "r124", "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r369", "r372", "r373", "r419", "r772", "r969", "r1035", "r1036" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiquidationBasisOfAccountingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiquidationBasisOfAccountingTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LiquidityandCapitalResources" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Capital Resources", "label": "Liquidation Basis of Accounting [Text Block]", "documentation": "The entire disclosure for the liquidation basis of accounting." } } }, "auth_ref": [ "r29" ] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r429", "r954" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "domh_LongTermEquityInvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "LongTermEquityInvestmentsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Long Term Equity Investments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long term equity investments", "verboseLabel": "Long-term investments, Carrying Value", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r100" ] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MajorityShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MajorityShareholderMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders [Member]", "label": "Majority Shareholder [Member]", "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketableSecuritiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total marketable securities", "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r918" ] }, "us-gaap_MarketableSecuritiesGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketableSecuritiesGainLossAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Gains and (Losses) on Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Gain on marketable securities, net", "verboseLabel": "Gain on marketable securities", "label": "Marketable Security, Gain (Loss)", "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized loss (gain) on marketable securities", "label": "Marketable Security, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gains and (Losses) on Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized (gain) loss on marketable securities", "terseLabel": "Unrealized gain (loss)", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r52" ] }, "domh_MaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "MaturityDate", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "documentation": "Maturity date.", "label": "Maturity Date" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r165", "r207", "r208", "r209", "r210", "r306", "r332", "r333", "r334", "r342", "r398", "r461", "r500", "r502", "r509", "r549", "r550", "r614", "r635", "r640", "r641", "r671", "r696", "r697", "r698", "r699", "r701", "r702", "r732", "r739", "r752", "r754", "r756", "r757", "r765", "r766", "r767", "r768", "r773", "r971", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r856" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r856" ] }, "domh_MessrAnthonyHayesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "MessrAnthonyHayesMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Messr. Anthony Hayes [Member]", "label": "Messr Anthony Hayes Member" } } }, "auth_ref": [] }, "domh_MessrChristopherDevallMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "MessrChristopherDevallMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Messr. Christopher Devall [Member]", "label": "Messr Christopher Devall Member" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r165", "r207", "r208", "r209", "r210", "r306", "r332", "r333", "r334", "r342", "r398", "r461", "r500", "r502", "r509", "r549", "r550", "r614", "r635", "r640", "r641", "r671", "r696", "r697", "r698", "r699", "r701", "r702", "r732", "r739", "r752", "r754", "r756", "r757", "r765", "r766", "r767", "r773", "r971", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "verboseLabel": "Non-controlling interests (in Dollars)", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r44", "r72", "r122", "r123", "r124", "r198", "r211", "r213", "r214", "r215", "r218", "r219", "r487", "r560", "r1024" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Membership interests", "verboseLabel": "Minority interest percentage", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r876" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r884" ] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NameChangeEventDateAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NameChangeEventLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NameChangeEventTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r857" ] }, "domh_NetCapitalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "NetCapitalAmount", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net capital requirement", "documentation": "The amount of net capital.", "label": "Net Capital Amount" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r56", "r57", "r58" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to common stockholders of Dominari Holdings Inc.", "verboseLabel": "Net gain attributable to common stock holders of Dominari Holdings", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r47", "r58", "r75", "r92", "r96", "r109", "r110", "r113", "r122", "r123", "r124", "r128", "r132", "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r150", "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r237", "r240", "r243", "r248", "r339", "r362", "r365", "r392", "r419", "r493", "r579", "r601", "r602", "r711", "r713", "r715", "r784", "r969" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net profit attributable to non-controlling interests", "verboseLabel": "Noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r28", "r67", "r109", "r110", "r140", "r143", "r144", "r492", "r923" ] }, "domh_NetProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "NetProceeds", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "documentation": "The amount of net proceeds.", "label": "Net Proceeds" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Recently adopted accounting standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r827", "r828", "r829", "r830" ] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r901" ] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r901" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "domh_NonControllingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "NonControllingInterestMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interest [Member]", "label": "Non Controlling Interest Member" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r856" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r811", "r822", "r838", "r864", "r873" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r847" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r846" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r864" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r884" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r884" ] }, "domh_NoncashWarrantRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "NoncashWarrantRevenue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash warrant revenue", "documentation": "The cash outflow from non cash warrant reserves.", "label": "Noncash Warrant Revenue" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Non controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r25", "r268", "r942", "r943", "r944", "r945", "r1060" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expenses)", "terseLabel": "Total other (expenses) income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r53" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expenses)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Notes receivable at fair value, current Balance beginning", "periodEndLabel": "Notes receivable at fair value, current Balance ending", "terseLabel": "Notes receivable, at fair value - current portion", "verboseLabel": "Notes receivable at fair value, current portion", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r465", "r956" ] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Notes receivable at fair value, non-current Balance beginning", "periodEndLabel": "Notes receivable at fair value, non-current Balance ending", "terseLabel": "Notes receivable, at fair value - non-current portion", "verboseLabel": "Notes receivable at fair value, non-current portion", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [ "r956", "r961", "r962" ] }, "domh_NotesReceivableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "NotesReceivableDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Receivable (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Notes Receivable, Fair Value Disclosure", "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date." } } }, "auth_ref": [ "r1020", "r1021", "r1022", "r1023" ] }, "us-gaap_NotesReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesReceivableNetAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable, at fair value", "label": "Financing Receivable, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r720", "r730", "r949" ] }, "domh_OperatingCostsAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "OperatingCostsAbstract0", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Costs", "label": "Operating Costs Abstract0" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating costs and expenses", "verboseLabel": "Operating Costs", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r715" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r79", "r711", "r715", "r719", "r948", "r950", "r951", "r952", "r953" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r439", "r771" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease rent expenses", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1027" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Payments [Abstract]", "terseLabel": "Long-term" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r435" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability - current", "verboseLabel": "Current Operating", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r435" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability, less current portion", "verboseLabel": "Long-term Operating", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r435" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows - operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r436", "r441" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "verboseLabel": "Operating lease right-of-use-assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r434" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r933" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r443", "r771" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term - operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r442", "r771" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business and Recent Developments", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r66", "r93", "r94", "r95", "r511", "r512" ] }, "domh_OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_OriginationOfLoansToEmployeeStockOwnershipPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OriginationOfLoansToEmployeeStockOwnershipPlans", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee loans", "label": "Origination of Loans to Employee Stock Ownership Plans", "documentation": "The cash outflow to finance the entity's defined contribution plan to acquire shares of the entity. The plan initially holds the shares in a suspense account, which is collateral for the loan. As the plan makes payment on the debt, the shares are released from the suspense account and become available to be allocated to participant accounts." } } }, "auth_ref": [ "r13" ] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense (in Dollars)", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r48", "r49", "r774", "r775" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expenses) income", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31", "r772" ] }, "domh_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "OtherMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other [Member]", "label": "Other Member" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income)/expenses", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r856" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Loans to employees", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r107", "r567", "r726", "r774", "r775", "r1048" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r802" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r809", "r820", "r836", "r871" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r812", "r823", "r839", "r874" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r812", "r823", "r839", "r874" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OwnershipAxis", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OwnershipDomain", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ParentEntityLegalName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ParentMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Holding Stockholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r845" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash paid for dividends", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r55" ] }, "us-gaap_PaymentsToAcquireLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireLoansReceivable", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Loans to employees", "label": "Payments to Acquire Loans Receivable", "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireLongtermInvestments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses on long term investments", "label": "Payments to Acquire Long-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": [ "r928" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r959" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r855" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r855" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r847" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r864" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r857" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r846" ] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PhoneFaxNumberDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameAxis", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r848" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r893" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r847" ] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r788" ] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r788" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r795" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r797" ] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r788" ] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r788" ] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of common stock issued upon conversion", "label": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r252" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidation preference (in Dollars per share)", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r20", "r21", "r38", "r935", "r937", "r973" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r776", "r777", "r780", "r781", "r782", "r783", "r1050", "r1060" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r38", "r250" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r38", "r558" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r38", "r250" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r38", "r558", "r578", "r1060", "r1061" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock value", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r38", "r239", "r245", "r484", "r772" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r922" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrivatePlacementMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of principal on note receivable", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r931" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from issuance of common stock", "verboseLabel": "Net proceeds (in Dollars)", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r930" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from issuance of common stock for warrants exercised", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r929" ] }, "domh_ProceedsfromCollectionofLoansToEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ProceedsfromCollectionofLoansToEmployees", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of loans to employees", "documentation": "Represent the amount of cash inflow of collection of loans to employees.", "label": "Proceedsfrom Collectionof Loans To Employees" } } }, "auth_ref": [] }, "us-gaap_ProfessionalAndContractServicesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfessionalAndContractServicesExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Professional and consulting fees", "label": "Professional and Contract Services Expense", "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "verboseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r92", "r96", "r109", "r110", "r117", "r122", "r123", "r124", "r128", "r132", "r140", "r143", "r144", "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r237", "r339", "r362", "r365", "r367", "r370", "r371", "r392", "r419", "r467", "r469", "r491", "r528", "r579", "r601", "r602", "r758", "r759", "r785", "r923", "r969" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r445", "r470", "r490", "r772" ] }, "domh_PurchaseOfShorttermAndLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "PurchaseOfShorttermAndLongtermInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of short-term and long-term investments", "documentation": "Purchase of short-term and long-term investments.", "label": "Purchase Of Shortterm And Longterm Investments" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r845" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r845" ] }, "domh_RaefanIndustriesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "RaefanIndustriesLLCMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails", "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Raefan Industries LLC [Member]", "label": "Raefan Industries LLCMember" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r165", "r207", "r208", "r209", "r210", "r294", "r306", "r332", "r333", "r334", "r338", "r342", "r398", "r458", "r460", "r461", "r500", "r502", "r509", "r549", "r550", "r614", "r635", "r640", "r641", "r671", "r696", "r697", "r698", "r699", "r701", "r702", "r732", "r739", "r752", "r754", "r756", "r757", "r765", "r766", "r767", "r768", "r773", "r778", "r967", "r971", "r1018", "r1038", "r1039", "r1040", "r1041", "r1042" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r165", "r207", "r208", "r209", "r210", "r294", "r306", "r332", "r333", "r334", "r338", "r342", "r398", "r458", "r460", "r461", "r500", "r502", "r509", "r549", "r550", "r614", "r635", "r640", "r641", "r671", "r696", "r697", "r698", "r699", "r701", "r702", "r732", "r739", "r752", "r754", "r756", "r757", "r765", "r766", "r767", "r768", "r773", "r778", "r967", "r971", "r1018", "r1038", "r1039", "r1040", "r1041", "r1042" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain (loss)", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r496" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Notes Receivable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReceivablesFromBrokersDealersAndClearingOrganizations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReceivablesFromBrokersDealersAndClearingOrganizations", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable from clearing brokers", "label": "Receivable from Broker-Dealer and Clearing Organization", "documentation": "Amount receivable from broker-dealers and clearing organizations, including, but not limited to, securities failed-to-deliver, certain deposits for securities borrowed, open transactions, good faith and margin deposits, commissions and floor brokerage receivables." } } }, "auth_ref": [ "r1044" ] }, "domh_ReceivablesFromClearingBrokersPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ReceivablesFromClearingBrokersPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable from Clearing Brokers", "documentation": "Disclosure of accounting policy for receivables from clearing brokers.", "label": "Receivables From Clearing Brokers Policy Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_ReceivablesFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReceivablesFromCustomers", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable from clearing brokers", "label": "Receivable from Customer in Brokerage", "documentation": "Amount due from customers for fees and charges arising from transactions related to the entity's brokerage activities and operations." } } }, "auth_ref": [ "r921", "r1045" ] }, "domh_RecognizedRevenueIncludedInContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "RecognizedRevenueIncludedInContractLiabilities", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized revenue included in contract liabilities", "documentation": "Represents the amount of recognized revenue included in contract liabilities.", "label": "Recognized Revenue Included In Contract Liabilities" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r804", "r815", "r831", "r866" ] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "RegistrationStatementAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": [ "r788" ] }, "srt_RegulatoryCapitalRequirementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RegulatoryCapitalRequirementsAbstract", "lang": { "en-us": { "role": { "label": "Regulatory [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Regulatory" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory", "label": "Regulatory Capital Requirements under Banking Regulations [Text Block]", "documentation": "The entire disclosure for regulatory capital requirement for depository and lending institutions. Institutions include, but not are not limited to, finance company, insured depository institution, bank holding company, savings and loan association holding company, bank and savings institution not federally insured, mortgage company, foreign financial institution and credit union." } } }, "auth_ref": [ "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479" ] }, "domh_RegulatoryDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "RegulatoryDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Regulatory (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyDomain", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r122", "r127", "r128", "r191", "r301", "r305", "r451", "r452", "r482", "r489", "r552", "r553", "r554", "r555", "r556", "r577", "r610", "r1058" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred fees", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r451" ] }, "domh_RelatedPartyTransactionDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "RelatedPartyTransactionDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r122", "r127", "r128", "r191", "r451", "r452", "r453", "r583", "r584", "r588" ] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revere\u2019s outstanding equity percentage", "label": "Related Party Transaction, Rate", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth_ref": [ "r1032" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transaction [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r122", "r127", "r128", "r191", "r301", "r305", "r451", "r452", "r482", "r489", "r552", "r553", "r554", "r555", "r556", "r577", "r610", "r1034", "r1058" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransaction" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r448", "r449", "r450", "r452", "r454", "r524", "r525", "r526", "r586", "r587", "r588", "r607", "r609" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r805", "r816", "r832", "r867" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r806", "r817", "r833", "r868" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r813", "r824", "r840", "r875" ] }, "domh_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "RestrictedStockAwardsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards [Member]", "label": "Restricted Stock Awards Member" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards [Member]", "verboseLabel": "Restricted Stock [Member]", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r947", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r42", "r62", "r486", "r507", "r508", "r522", "r559", "r772" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r89", "r91", "r92", "r129", "r130", "r131", "r133", "r140", "r142", "r144", "r199", "r200", "r201", "r236", "r339", "r351", "r352", "r359", "r360", "r361", "r363", "r364", "r365", "r379", "r381", "r382", "r384", "r390", "r430", "r433", "r504", "r506", "r529", "r1060" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue disaggregated", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r77", "r78", "r158", "r172", "r173", "r180", "r184", "r187", "r189", "r190", "r288", "r289", "r290", "r463" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r86", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r704" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r86", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r290", "r293" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r77", "r78", "r114", "r122", "r123", "r124", "r158", "r172", "r173", "r180", "r184", "r187", "r189", "r190", "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r419", "r467", "r469", "r725", "r760", "r774", "r775", "r969" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenuesAbstract", "lang": { "en-us": { "role": { "label": "Revenue [Abstract]" } } }, "auth_ref": [] }, "domh_RevereSecuritiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "RevereSecuritiesLLCMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revere Securities, LLC [Member]", "label": "Revere Securities LLCMember" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r884" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r884" ] }, "domh_SaleOfLongtermEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SaleOfLongtermEquityInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of long-term equity investments", "documentation": "Sale of long-term equity investments.", "label": "Sale Of Longterm Equity Investments" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofNotesReceivableTable" ], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": [ "r40", "r46", "r192", "r957" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notes Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r40", "r46" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r154" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NetIncomeLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r15" ] }, "domh_ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities That Are Measured At Fair Value Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCapitalizationLongtermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfCapitalizationLongtermDebtLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "domh_ScheduleOfComputationOfDilutedLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfComputationOfDilutedLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Computation Of Diluted Loss Per Share Abstract" } } }, "auth_ref": [] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r195", "r196", "r197", "r358", "r419", "r910", "r911", "r912", "r1008", "r1009", "r1010", "r1011" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities that are Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1015", "r1016" ] }, "domh_ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Financial Assets That Are Measured At Fair Value On ARecurring Basis Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermEquityInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r632", "r634", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680" ] }, "domh_ScheduleOfLongTermEquityInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfLongTermEquityInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Long Term Equity Investments Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfNotesReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfNotesReceivableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Notes Receivable Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfRestrictedStockAwardsActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfRestrictedStockAwardsActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Stock Awards Activity Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenueAndNetLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfSegmentProfitabilityThatAreMostReliedUponByTheCodmAreGrossRevenueAndNetLossAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Segment Profitability That Are Most Relied Upon By The Codm Are Gross Revenue And Net Loss Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r16", "r17", "r18" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r16", "r17", "r18" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Activity Under the Company\u2019s Stock Option Plan", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r7", "r8", "r63" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Awards Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r990" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrant Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r975" ] }, "domh_ScheduleOfTotalRevenueDisaggregatedByRevenueTypeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfTotalRevenueDisaggregatedByRevenueTypeAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Total Revenue Disaggregated By Revenue Type Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfWarrantActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ScheduleOfWarrantActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Activity Abstract" } } }, "auth_ref": [] }, "domh_SecuritiesPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SecuritiesPurchaseAgreementsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreements [Member]", "label": "Securities Purchase Agreements Member" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r789" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r793" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposit", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r917" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r792" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r798" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r170", "r724", "r731" ] }, "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description", "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description", "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource." } } }, "auth_ref": [ "r179", "r721", "r728" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r80", "r158", "r166", "r167", "r168", "r169", "r171", "r176", "r177", "r178", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r720", "r722", "r723", "r725", "r727", "r729", "r730" ] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "domh_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SeriesAWarrantsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Warrants [Member]", "label": "Series AWarrants Member" } } }, "auth_ref": [] }, "domh_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SeriesBWarrantsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B Warrants [Member]", "label": "Series BWarrants Member" } } }, "auth_ref": [] }, "domh_SeriesD1ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SeriesD1ConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D-1 Convertible Preferred Stock [Member]", "documentation": "Series D1 Convertible Preferred Stock Member.", "label": "Series D1 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "domh_SeriesD1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SeriesD1PreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Series D-1 Convertible Preferred Stock", "label": "Series D1 Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesDPreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D Convertible Preferred Stock", "verboseLabel": "Series D Convertible Preferred Stock [Member]", "label": "Series D Preferred Stock [Member]", "documentation": "Series D preferred stock." } } }, "auth_ref": [ "r919", "r920", "r972", "r974" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Option Activity Under the Company\u2019s Stock Option Plan [Abstract]" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, Weighted Average Exercise Price", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards expired during the period on other than stock (or unit) option plans.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expiration Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Warrants", "verboseLabel": "Number of Restricted Stock Awards, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r323" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Grant Day Fair Value, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r323" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of shares, ending balance", "periodStartLabel": "Number of shares, beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r320", "r321" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average per share, ending balance", "periodStartLabel": "Weighted Average per share, beginning balance", "terseLabel": "Weighted Average per share, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r320", "r321" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r324" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested fair value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r327" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r324" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used in the Company\u2019s Fair Value Analysis [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssumptionsUsedintheCompanysFairValueAnalysisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssumptionsUsedintheCompanysFairValueAnalysisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r334" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Awards Activity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r338" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired, Warrants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options expired, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r327" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee options expired, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r319" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee options forfeited, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r318" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfietedInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfietedInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options forfeited, Total Intrinsic Value", "documentation": "Employee options forfeited, Intrinsic Value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfieted In Period Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Number of Shares", "verboseLabel": "Granted shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r316" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r312", "r313" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r312", "r313" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r329" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r329" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r329" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r332", "r333", "r334", "r335" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options expired, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r319" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options forfeited, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r316" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssumptionsUsedintheCompanysFairValueAnalysisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying stock price (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExercised", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, Total Intrinsic Value", "documentation": "Exercised, total intrinsic value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Option Aggregate Intrinsic Value Exercised" } } }, "auth_ref": [] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExpiration", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, Total Intrinsic Value", "documentation": "Intrinsic value of expired award under share-based payment arrangement. Excludes share and unit options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Option Aggregate Intrinsic Value Expiration" } } }, "auth_ref": [] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrants", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Total Intrinsic Value", "documentation": "Amount of aggregate intrinsic value grants under other than options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Grants" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1007" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssumptionsUsedintheCompanysFairValueAnalysisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated maturity date", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r331" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r65" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable, Weighted Average Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r329" ] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Total Intrinsic Value", "documentation": "Employee options granted, Total Intrinsic Value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Granted Weighted Average Remaining Contractual Term1" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease rent expense", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r440", "r771" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r120", "r121" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r796" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r87", "r104", "r105", "r106", "r122", "r124", "r148", "r149", "r151", "r153", "r160", "r161", "r198", "r211", "r213", "r214", "r215", "r218", "r219", "r238", "r239", "r241", "r242", "r244", "r247", "r250", "r251", "r255", "r258", "r266", "r419", "r517", "r518", "r519", "r520", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r542", "r558", "r580", "r603", "r685", "r686", "r687", "r688", "r689", "r909", "r937", "r939", "r946" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r39", "r43", "r44", "r89", "r91", "r92", "r111", "r112", "r113", "r129", "r130", "r131", "r133", "r140", "r142", "r144", "r159", "r199", "r200", "r201", "r236", "r268", "r339", "r351", "r352", "r359", "r360", "r361", "r363", "r364", "r365", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r433", "r447", "r494", "r504", "r505", "r506", "r529", "r603" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r129", "r130", "r131", "r159", "r238", "r239", "r241", "r244", "r433", "r463", "r513", "r530", "r542", "r551", "r552", "r553", "r554", "r555", "r556", "r558", "r561", "r562", "r563", "r564", "r565", "r568", "r569", "r570", "r571", "r573", "r574", "r575", "r576", "r577", "r581", "r582", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r603", "r713", "r715", "r779", "r1058" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r129", "r130", "r131", "r159", "r191", "r238", "r239", "r241", "r244", "r433", "r463", "r513", "r530", "r542", "r551", "r552", "r553", "r554", "r555", "r556", "r558", "r561", "r562", "r563", "r564", "r565", "r568", "r569", "r570", "r571", "r573", "r574", "r575", "r576", "r577", "r581", "r582", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r603", "r713", "r715", "r779", "r1058" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r808", "r819", "r835", "r870" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in Shares)", "verboseLabel": "Number of shares issued", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r38", "r39", "r62", "r517", "r603", "r686" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under Advisory Agreements (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r6", "r38", "r39", "r62" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock from warrants exercised (in Shares)", "negatedLabel": "Exercised, Warrants", "verboseLabel": "Additional common stock issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r6", "r38", "r39", "r62", "r317" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "verboseLabel": "Fair value of issued shares (in Dollars)", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r6", "r38", "r39", "r62", "r529", "r603", "r686", "r785" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock from warrants exercised", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r6", "r39", "r43", "r44", "r62" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment gain amount", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r6" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under Advisory Agreements", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r6", "r38", "r39", "r62", "r529", "r603", "r688", "r785" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r25", "r26", "r27", "r89", "r90", "r91", "r92", "r112", "r129", "r130", "r131", "r133", "r140", "r142", "r199", "r200", "r201", "r236", "r268", "r339", "r351", "r352", "r359", "r360", "r361", "r363", "r364", "r365", "r379", "r380", "r381", "r382", "r383", "r384", "r390", "r423", "r424", "r428", "r431", "r447", "r505", "r506", "r527", "r560", "r578", "r604", "r605", "r690", "r774", "r775", "r785", "r935", "r939", "r940", "r960", "r1024", "r1060" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity and Convertible Preferred Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r60", "r249", "r251", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r268", "r378", "r389", "r606", "r608", "r691" ] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) [Table]" } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockScheduleofRestrictedStockAwardsActivityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "StockholdersEquityandConvertiblePreferredStockScheduleofRestrictedStockAwardsActivityDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsegmentsAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsegmentsDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "domh_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r863" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r955", "r1033" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r855" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r862" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r883" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r885" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r886" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r887" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r887" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r885" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r885" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r888" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r886" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r22" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "terseLabel": "Treasury stock, at cost", "verboseLabel": "Treasury stock", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r22" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, as of cost, 60,148 shares as of June 30, 2025 and December 31, 2024", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r22", "r23", "r39", "r43" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r366" ] }, "domh_UnderwritingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "UnderwritingMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting [Member]", "label": "Underwriting Member" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r882" ] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain", "label": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r4", "r597", "r598", "r599", "r600", "r661" ] }, "domh_UnrealizedGainlossOnNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "UnrealizedGainlossOnNotesReceivable", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on notes receivable", "documentation": "The amount of unrealized gain (loss) on notes receivable.", "label": "Unrealized Gainloss On Notes Receivable" } } }, "auth_ref": [] }, "domh_UnrealizedLossOnNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20250630", "localname": "UnrealizedLossOnNoteReceivable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofSegmentProfitabilitythatareMostReliedUponbytheCODMareGrossRevenueandNetLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized loss on note receivable", "documentation": "Amount of (loss) on sale of unrealized financing receivable.", "label": "Unrealized Loss On Note Receivable" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r83", "r84", "r162", "r163", "r164", "r165", "r467", "r469", "r717" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r851" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofComputationofDilutedLossPerShareTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r776", "r777", "r780", "r781", "r782", "r783" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of warrants", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1017", "r1018", "r1019" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r147", "r153" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, basic and diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r146", "r153" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r899" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r849" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-30/tableOfContent" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1D" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1F" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481019/946-20-45-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-5" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-5" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-5" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r908": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r909": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r910": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r912": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/321/tableOfContent" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481913/940-20-25-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481833/940-20-45-3" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "310", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-310/tableOfContent" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } } ZIP 77 0001213900-25-074425-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-25-074425-xbrl.zip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ea0252311-10q_dominari_htm.xml IDEA: XBRL DOCUMENT 0000012239 2025-01-01 2025-06-30 0000012239 2025-08-08 0000012239 2025-06-30 0000012239 2024-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2025-06-30 0000012239 us-gaap:SeriesDPreferredStockMember 2024-12-31 0000012239 domh:SeriesD1PreferredStockMember 2025-06-30 0000012239 domh:SeriesD1PreferredStockMember 2024-12-31 0000012239 2025-04-01 2025-06-30 0000012239 2024-04-01 2024-06-30 0000012239 2024-01-01 2024-06-30 0000012239 us-gaap:PreferredStockMember 2025-03-31 0000012239 us-gaap:CommonStockMember 2025-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2025-03-31 0000012239 us-gaap:RetainedEarningsMember 2025-03-31 0000012239 us-gaap:ParentMember 2025-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2025-03-31 0000012239 2025-03-31 0000012239 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000012239 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000012239 us-gaap:ParentMember 2025-04-01 2025-06-30 0000012239 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0000012239 us-gaap:PreferredStockMember 2025-06-30 0000012239 us-gaap:CommonStockMember 2025-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-06-30 0000012239 us-gaap:RetainedEarningsMember 2025-06-30 0000012239 us-gaap:ParentMember 2025-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-06-30 0000012239 us-gaap:PreferredStockMember 2024-03-31 0000012239 us-gaap:CommonStockMember 2024-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-03-31 0000012239 us-gaap:RetainedEarningsMember 2024-03-31 0000012239 us-gaap:ParentMember 2024-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2024-03-31 0000012239 2024-03-31 0000012239 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000012239 us-gaap:ParentMember 2024-04-01 2024-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0000012239 us-gaap:PreferredStockMember 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-06-30 0000012239 us-gaap:ParentMember 2024-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-06-30 0000012239 2024-06-30 0000012239 us-gaap:PreferredStockMember 2024-12-31 0000012239 us-gaap:CommonStockMember 2024-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-12-31 0000012239 us-gaap:RetainedEarningsMember 2024-12-31 0000012239 us-gaap:ParentMember 2024-12-31 0000012239 us-gaap:NoncontrollingInterestMember 2024-12-31 0000012239 us-gaap:PreferredStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-06-30 0000012239 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0000012239 us-gaap:ParentMember 2025-01-01 2025-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-06-30 0000012239 us-gaap:PreferredStockMember 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember